US20180104192A1 - Layered Bodies, Compositions Containing Them and Process for Producing Them - Google Patents
Layered Bodies, Compositions Containing Them and Process for Producing Them Download PDFInfo
- Publication number
- US20180104192A1 US20180104192A1 US15/833,436 US201715833436A US2018104192A1 US 20180104192 A1 US20180104192 A1 US 20180104192A1 US 201715833436 A US201715833436 A US 201715833436A US 2018104192 A1 US2018104192 A1 US 2018104192A1
- Authority
- US
- United States
- Prior art keywords
- fluid medium
- channel
- optionally
- process according
- needles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 69
- 239000000203 mixture Substances 0.000 title description 16
- 239000012530 fluid Substances 0.000 claims description 188
- 239000002775 capsule Substances 0.000 claims description 54
- 239000007788 liquid Substances 0.000 claims description 53
- 229920000642 polymer Polymers 0.000 claims description 42
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 14
- 239000000032 diagnostic agent Substances 0.000 claims description 13
- 229940039227 diagnostic agent Drugs 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 10
- 150000008282 halocarbons Chemical class 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 229920001610 polycaprolactone Polymers 0.000 claims description 7
- 239000004632 polycaprolactone Substances 0.000 claims description 7
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 229920000249 biocompatible polymer Polymers 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 239000007789 gas Substances 0.000 description 36
- -1 polyoxyethylene Polymers 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 17
- 229960004624 perflexane Drugs 0.000 description 13
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 13
- 238000005259 measurement Methods 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 229960004692 perflenapent Drugs 0.000 description 5
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 5
- 239000003586 protic polar solvent Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000004626 scanning electron microscopy Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000011344 liquid material Substances 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- MXRGSJAOLKBZLU-UHFFFAOYSA-N 3-ethenylazepan-2-one Chemical compound C=CC1CCCCNC1=O MXRGSJAOLKBZLU-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 229920001685 Amylomaize Polymers 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 244000017020 Ipomoea batatas Species 0.000 description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229920004482 WACKER® Polymers 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920001083 polybutene Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229960002796 polystyrene sulfonate Drugs 0.000 description 2
- 239000011970 polystyrene sulfonate Substances 0.000 description 2
- 235000019448 polyvinylpyrrolidone-vinyl acetate copolymer Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 229940047670 sodium acrylate Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000003075 superhydrophobic effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 2
- 229920003176 water-insoluble polymer Polymers 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- OKIYQFLILPKULA-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluoro-4-methoxybutane Chemical group COC(F)(F)C(F)(F)C(F)(F)C(F)(F)F OKIYQFLILPKULA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 238000001327 Förster resonance energy transfer Methods 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000009021 linear effect Effects 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000009022 nonlinear effect Effects 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/20—After-treatment of capsule walls, e.g. hardening
- B01J13/22—Coating
-
- B29C47/065—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/16—Articles comprising two or more components, e.g. co-extruded layers
- B29C48/18—Articles comprising two or more components, e.g. co-extruded layers the components being layers
- B29C48/21—Articles comprising two or more components, e.g. co-extruded layers the components being layers the layers being joined at their surfaces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2933—Coated or with bond, impregnation or core
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2933—Coated or with bond, impregnation or core
- Y10T428/2938—Coating on discrete and individual rods, strands or filaments
Definitions
- the present invention relates to layered bodies, which may be in capsule or thread form, that typically have a size in the micro- or nanometer scale.
- Micro- or nanometre scale multilayer particles, capsules and fibres are of increasing interest in a number of fields, including diagnostic and therapeutic applications. They can be used, for example, to deliver therapeutic agents, contrast agents, living cells, and other species to desired sites in vivo. Because of their small size, it is a considerable challenge to create the micro- or nanometre scale multilayer particles, capsules and fibres with specific properties. Some methods of manufacturing the micro- or nanoscale species, while appearing initially promising, have suffered from their requirement to use surfactants or certain additives. It would be desirable to produce micro- or nanometer scale multilayer particles, capsules and fibres without surfactants or potentially harmful additives.
- micro- or nanometer scale multilayer capsules and fibres are as carriers for a specific agent, e.g. a therapeutic or diagnostic agent.
- Conventional carriers e.g. those used in macroscale drug delivery applications, are limited in their performance for a number of reasons, and may not be suitable for use in the techniques for making the micro- or nanometer scale multilayer particles, capsules and fibres.
- Layer by layer deposition commonly requires selecting appropriate materials for adjacent layers so that they interact and adhere to one another, e.g. having adjacent layers comprising species of opposing charges or adjacent layers that rely on hydrogen bonding.
- Layer by layer deposition techniques are described, for example, in US 2005/0208100 and US 2005/0163714, both of which are incorporated herein by reference in their entirety.
- a drawback of layer by layer deposition is the considerable time it takes to produce the multilayered species, and the required use of certain material to produce the adherence between adjacent layers. Additionally, they typically use a crystalline material as a core, which leads to a non-spherical core in the final multilayered species.
- microbubbles Hollow particles of the micro or nanometer scale, sometimes termed microbubbles, have also been found useful in certain applications. They are sometimes used as contrast agents in ultrasound. Recent investigations have been made into the use of microbubbles for the treatment and assessment of cancer. This is achieved by loading a desired agent on the surface of the bubble or cavity, which collapses with the application of ultra-sound at the desired site, enabling site-specific release of the agent.
- the present invention provides a layered body comprising:
- the layered body may be in the form of a capsule.
- the layered body may be in the form of a thread.
- “intermediate” indicates that a layer is disposed between the core region and the outer layer.
- the outer layer will typically encompass the whole of the core region, at least in a cross section of the body, and the intermediate layer or layers will be disposed between the outer layer and the core region
- the present invention provides a layered body comprising:
- the layered body having at least one dimension, measured across the body and through the core region, of 100 ⁇ m or less.
- the layered body may be in the form of a capsule.
- the layered body may be in the form of a thread.
- “intermediate” indicates that a layer is disposed between the core region and the outer layer.
- the outer layer will typically encompass the whole of the core region, at least in a cross section of the body, and the intermediate layer or layers will be disposed between the outer layer and the core region.
- “Substantially circular” can include a circular shape and non-circular shapes, such as an oval shape.
- the present invention provides an electrohydrodynamic device for producing one or more layered bodies
- intermediate indicates that a channel is disposed concentrically between the core channel and the outer channel.
- Concentrically indicates that intermediate channels surround the core channel and, in turn, the outer channel surrounds the intermediate channels; in an embodiment, all the channels may share the same geometric centre or axis, but this need not necessarily be the case.
- the present invention provides a process for producing one or more layered bodies, the process
- an electrohydrodynamic device comprising at least three concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least one intermediate concentrically disposed tubular channel, and an outer concentrically disposed tubular channel,
- the device of this aspect comprises at least four concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least two intermediate concentrically disposed tubular channels, and an outer concentrically disposed tubular channel, and the fluid medium passed through at least one of the at least two intermediate concentrically disposed tubular channels is the second fluid medium, and optionally the fluid medium passed through the core channel is the second fluid medium; and optionally the fluid medium passed through the remaining channels is selected from the first fluid medium and the second fluid medium and is preferably the first fluid medium.
- intermediate indicates that a channel is disposed concentrically between the core channel and the outer channel.
- Concentrically indicates that intermediate channels surround the core channel and, in turn, the outer channel surrounds the intermediate channels; in an embodiment, all the channels may share the same geometric centre or axis, but this need not necessarily be the case.
- the present invention further provides a layered body obtainable by the process according to the fourth aspect.
- the present invention provides a process for producing one or more layered bodies, the process comprising:
- the one or more layered bodies may be one or more layered bodies according to the second aspect.
- “intermediate” indicates that a channel is disposed concentrically between the core channel and the outer channel.
- the fluid mediums may be selected from a first fluid medium comprising a liquid comprising a non-volatile component and a second fluid medium comprising or consisting of a volatile liquid.
- “Concentrically”, in the present context, indicates that intermediate channels surround the core channel and, in turn, the outer channel surrounds the intermediate channels; in an embodiment, all the channels may share the same geometric centre or axis, but this need not necessarily be the case.
- the present invention further provides a layered body obtainable by the process according to the fifth aspect.
- the present invention provides a composition comprising a plurality of bodies of the first aspect and/or a plurality of bodies of the second aspect.
- the layered bodies of the first aspect have advantages over the prior art. They find use in many applications, such as drug delivery, catalysis and protecting sensitive agents. For example, it is considered that they can be used in ultrasound and can increase the non-linear effect of an ultrasound diagnostic. They can also have many layers, which could have differing properties, and, in some embodiments, a gas-containing core region and a gas-containing intermediate layer, which enables selective destruction of the layers, which may be used to release different active agents, e.g. therapeutic or diagnostic agents, at different times.
- the layered bodies of the second aspect have advantages over the prior art, especially multilayered bodies produced using layer-by-layer techniques.
- the layered bodies of the second aspect can be formed much quicker than those of the layer-by-layer techniques, for example in electrohydrodynamic processes, e.g. a process of the fourth or fifth aspect.
- the removal of the core region in layer-by-layer formed bodies also involves techniques that can be detrimental to the bodies and/or involve agents that could be harmful if the layered body is used as a pharmaceutical, whereas the layered bodies produced in accordance with the present invention can avoid such difficulties.
- the present inventors have also found that the processes described herein allow a greater control of the thickness of the various layers, and therefore the volume of material in the various layers, than at least some of the processes described in the prior art.
- the control of the thickness of layers is also advantageous in being able to more closely control the energy absorption characteristics of the layered bodies, which can be useful in ultrasound applications.
- FIG. 1 shows an embodiment of the device of the present invention, the embodiment comprising a four-needle electrohydrodynamic system.
- FIGS. 2A and 2B shows the four-needle electrohydrodynamic system of FIG. 1 in more detail, the use of which is described in the detailed description and Examples below.
- FIGS. 3A and 3B shows photographs of the needles used in the electrohydrodynamic system of FIGS. 1 and 2 , with FIG. 3A showing the separate needles, and FIG. 3B showing the needles assembled.
- FIGS. 4A to 4D show schematic cross-sectional views of embodiments of the layered bodies of the present invention.
- FIG. 5 shows an embodiment of a composition comprising a plurality of layered bodies of the present invention, in particulate or capsule form, obtained as described in the Examples below.
- FIG. 6 shows an embodiment of a composition comprising a plurality of layered bodies of the present invention, in particulate or capsule form, obtained as described in the Examples below.
- FIG. 7 shows the cross section of either capsule or a thread and how the diameter of the capsule or thread can be measured, for example either at the widest point (horizontal diameter in this Figure) or at its narrowest point (vertical diameter in this Figure).
- FIG. 8 shows the layered body of FIG. 4B , with the core region R C and surrounding intermediate layer R I1 having shifted due to gravity within the gas-containing layer R I2 , such that it is in contact with the outer layer R O .
- FIG. 9 shows the layered body of 4 C, with the with the core region R C and surrounding intermediate layer R I1 having shifted due to gravity within the gas-containing layer R I2 , such that it is in contact with the outer layer R O .
- the present invention provides a layered body comprising:
- At least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ⁇ m or less.
- the core region may have a substantially circular cross section.
- the layered body of the first aspect may be producible from the process of fourth aspect. This has typically been found to produce a core region having a substantially circular cross section.
- the at least one intermediate layer least partially surrounds, optionally completely surrounds, the core region.
- the outer layer at least partially surrounds, optionally completely surrounds, the at least one intermediate layer.
- the outer layer surrounds at least part of, optionally all of the, the core region.
- the at least one intermediate layer and the outer layer share the same core region.
- the at least one intermediate layer and the outer layer are disposed concentrically around the core region.
- “disposed concentrically”, indicates that the at least one intermediate layer surrounds the core region and the outer layer surrounds the at least one intermediate layer; “disposed concentrically” covers embodiments where the core region is circular in cross section and non-circular in cross section.
- “disposed concentrically” indicates that the core region and the at least one intermediate layer share the same core, but they need not necessarily share the same geometric centre (for example when the body is in the form of a capsule) or axis (for example when in the body is in the form of a thread).
- the intermediate layer disposed closest to the core is surrounded at least partially, optionally completely, by the other intermediate layer or layers.
- the outer layer preferably at least partially, optionally completely, surrounds the intermediate layers.
- the core region may be any suitable shape. It may or may not have a circular cross section. It may or may not have an oval cross section.
- the core region may or may not be spherical or approximately spherical in shape.
- the core region may have a shape selected from spherical, substantially spherical, spheroid, ellipsoidal and substantially ellipsoid.
- the core region may be elongated in shape.
- the layered body may be in the form of a capsule.
- the core region of the capsule may have a shape selected from spherical, substantially spherical, spheroid, ellipsoidal and substantially ellipsoid.
- the capsule may have core region that is encompassed, e.g. partially or entirely, by the least one intermediate layer, which, in turn, is or are (if there is more than one intermediate layer) encompassed by the outer layer.
- the capsule may have a substantially spherical core region, with the at least one intermediate layer and the outer layer in the form of approximate spheres arranged around, e.g. concentrically around, the core region.
- the at least one dimension measured across the body may be the diameter across the capsule, optionally the largest diameter.
- the measurement may be made for example by obtaining an image of the capsule using a suitable means, such as scanning electron microscopy, and measuring the diameter across the capsule. This is illustrated on a schematic drawing of a layered body in FIG. 7 .
- the diameter of the body can be measured at its widest point (horizontal diameter in FIG. 7 ) or at its narrowest point (vertical diameter in FIG. 7 ).
- the layered body may be in an elongated form.
- the body may have an elongated core, with the at least one intermediate layer disposed around, e.g. radially around, the elongated core, and the outer layer disposed around, e.g. radially around, the at least one intermediate layer.
- the at least one intermediate layer may extend along at least part of, optionally the whole of, the length of the core region.
- the outer layer may extend along at least part of, optionally whole of, the length of the core region.
- the body When the body is elongate, it may have two opposing ends.
- the at least one intermediate layer may or may not cover one or both ends of the core region of elongate body.
- the outer layer may or may not cover one or both ends of elongate body.
- the body may have an elongated core having an axis, and the at least one intermediate layer and the outer layer being disposed around, e.g. radially around, the axis, with the intermediate layer being disposed between the outer layer and the core region.
- the body may have an elongated core region having an axis, and the at least one intermediate layer and the outer layer being disposed concentrically around, the axis.
- the elongated form may, for example, be in the form of an elongated particle or in the form of a thread.
- the at least one dimension measured across the body may be a diameter of the elongated form, measured in a direction perpendicular to the axis. If the body is in the form of a thread, the at least one dimension measured across the body may be the diameter of the thread.
- the measurement may be made for example by obtaining an image of the thread using a suitable means, such as a scanning electron microscopy, and measuring the diameter of the thread.
- the core region and the outer layer each independently comprises a solid or a liquid medium, and the at least one intermediate layer comprises a gas.
- the body comprises at least two intermediate layers, the core region and the outer layer each independently comprises a solid or a liquid medium, at least one of the intermediate layers comprises a gas and at least one of the intermediate layers comprises a solid or liquid medium.
- At least two intermediate layers are disposed around, optionally concentrically around, the core region.
- the core comprises or consists of a gas.
- an intermediate layer disposed adjacent the core region defines a hollow core region, and the hollow core region comprises or consists of a gas.
- at least two intermediate layers are disposed around, optionally concentrically around, the core region, an intermediate layer disposed adjacent the core region defines a hollow core region, the hollow core region comprising a gas, and one or more of the other intermediate layers comprises a gas.
- the layered body may be formed according to the process of the fourth or fifth aspect and the gas in the at least one intermediate layer, and optionally in the core region (if it contains a gas), may comprise (i) a gas from the environment into which the fluid mediums pass into when exiting the channels and/or (ii) a gas formed from the vaporisation of the volatile liquid of the second fluid medium, which may be as described herein.
- the core region comprises or consists of a first gas
- at least two intermediate layers are disposed around, optionally concentrically around, the core region, the intermediate layer disposed adjacent the core region comprising a solid or a liquid medium, and at least one of the further outwardly disposed intermediate layers comprises a second gas.
- the first and second gas may be the same or different.
- the present invention provides a layered body comprising:
- the layered body having at least one dimension, measured across the body and through the core region, of 100 ⁇ m or less.
- the layered body may be in the form of a capsule.
- the layered body may be in the form of a thread.
- the layered body of the second aspect may be producible from the process of the fifth aspect. This has typically been found to produce a core region having a substantially circular cross section.
- one of the intermediate layers least partially surrounds, optionally completely surrounds, the core region.
- the intermediate layer disposed closest to the core is surrounded at least partially, optionally completely, by the other intermediate layer or layers.
- the outer layer preferably at least partially, optionally completely, surrounds the intermediate layers.
- the outer layer surrounds at least part of, optionally all of the, the core region.
- the at least two intermediate layers and the outer layer share the same core region.
- the at least two intermediate layers and the outer layer are disposed concentrically around the core region.
- “disposed concentrically”, indicates that the at least two intermediate layers surround the core region and the outer layer surrounds the at least two intermediate layers; “disposed concentrically” covers embodiments where the core region is circular in cross section and non-circular in cross section.
- “disposed concentrically” indicates that the core region and the at least two intermediate layers share the same core, but they need not necessarily share the same geometric centre or axis.
- the core region comprises or consists of a gas.
- an intermediate layer disposed adjacent the core region defines a hollow core region, and the hollow core region comprises or consists of a gas.
- At least one of the at least two intermediate layers comprises a gas.
- the core region and at least one of the at least two intermediate layers comprise a gas.
- the gas in the at least one intermediate layer and/or the core region comprises a gas selected from oxygen and nitrogen.
- At least one of the core region, the intermediate layer or layers and the outer layer may comprise one or more solid or liquid substances. At least one of the core region, the intermediate layer or layers and the outer layer may comprise one or more pharmaceutically acceptable substances.
- the one or more solid or liquid substances may be carrier substances, suitable for acting as carriers for one or more active agents, optionally agents selected from diagnostic and therapeutic agents.
- the one or more solid or liquid substances may be or comprise an organic substance, optionally a polymer.
- the one or more solid or liquid substances preferably comprise a biocompatible carrier substance.
- the one or more solid or liquid substances may be selected from poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polymethylsilsesquioxane (PMSQ), perfluorohexane (PFH), perfluoropentane (PFP), polyurethane, starch, albumin, polyethylene oxide (PEO), glycerol and oil, such as olive oil.
- PLGA poly(lactic-co-glycolic acid)
- PCL polycaprolactone
- PMSQ polymethylsilsesquioxane
- PH perfluorohexane
- PFP perfluoropentane
- polyurethane starch
- albumin polyethylene oxide
- PEO polyethylene oxide
- glycerol such as olive oil.
- Particularly preferred polymers include, but are not limited to sodium polystyrene sulfonate (PSS), polyethers, such as a polyethylene oxide (PEO), polyoxyethylene glycol or polyethylene glycol (PEG), polyethylene imine (PEI), a biodegradable polymer such as a polylactic acid, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) (PLGA), polymethylsilsesquioxane (PMSQ) and copolymers, derivatives, and mixtures thereof.
- PPS sodium polystyrene sulfonate
- PES polyethers
- PEO polyethylene oxide
- PEG polyoxyethylene glycol or polyethylene glycol
- PEI polyethylene imine
- a biodegradable polymer such as a polylactic acid, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) (PLGA), polymethylsilsesquioxane (PMSQ
- the polymer may have a property selected from: being positively-charged being (cationic), being negatively-charged (anionic), being polyethylene glycol(PEG)-ylated, being covered with a zwitterion, being hydrophobic, being superhydrophobic (for example having with water contact angles in excess of 150°), being hydrophilic, being superhydrophilic (for example, where the water contact angle is near or at 0°), being olephobic/lipophobic, being olephilic/lipophilic, and/or nanostructured, among others.
- the polymer may be a water-soluble and/or hydrophilic polymer, which may be selected from biocompatible polymers, including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and mixtures thereof.
- biocompatible polymers including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and mixtures thereof.
- biocompatible polymers including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including
- the polymer may also be selected from polyvinylpyrrolidone, vinyl acetate, polyvinylpyrrolidone-vinyl acetate copolymers, polyvinyl alcohol (PVA), acrylates and polyacrylic acid (PAA), including polyacrylate polymer, vinylcaprolactam/sodium acrylate polymers, methacrylates, poly(acryl amide-co-acrylic acid) (PAAm-co-AA), vinyl acetate and crotonic acid copolymers, polyacrylamide, polyethylene phosphonate, polybutene phosphonate, polystyrene, polyvinylphosphonates, polyalkylenes, and carboxy vinyl polymer.
- the multiphasic fiber compositions may comprise derivatives, copolymers, and further combinations of such polymers, as well.
- the polymer may be selected from water insoluble or hydrophobic polymers including, but not limited to, cellulose acetate, cellulose nitrate, ethylene-vinyl acetate copolymers, vinyl acetate homopolymer, ethyl cellulose, butyl cellulose, isopropyl cellulose, shellac, hydrophobic silicone polymer (e.g., dimethylsilicone), polymethyl methacrylate (PMMA), cellulose acetate phthalate and natural or synthetic rubber; siloxanes, such as polydimethylsiloxane (PMDS), cellulose, polyethylene, polypropylene, polyesters, polyurethane and nylon, including copolymers, derivatives, and combinations thereof.
- water insoluble or hydrophobic polymers including, but not limited to, cellulose acetate, cellulose nitrate, ethylene-vinyl acetate copolymers, vinyl acetate homopolymer, ethyl cellulose, butyl cellulose, isopropyl
- the polymers may be crosslinked, optionally after formation of the body, for example by the application of heat, ionizing radiation or other methods of curing and treating polymers known to those of skill in the art.
- the polymer may be selected from sodium alginate, carrageenan, xanthan gum, gum acacia, Arabic gum, guar gum, pullulan, agar, chitin, chitosan, pectin, karaya gum, locust bean gum, various polysaccharides; starches such as maltodextrin, amylose, corn starch, potato starch, rice starch, tapioca starch, pea starch, sweet potato starch, barley starch, wheat starch, modified starch (e.g., hydroxypropylated high amylose starch), dextrin, levan, elsinan and gluten; and proteins such as collagen, whey protein isolate, casein, milk protein, soy protein, keratin, and gelatin.
- starches such as maltodextrin, amylose, corn starch, potato starch, rice starch, tapioca starch, pea starch, sweet potato starch, barley starch, wheat star
- the layered body may comprise an active agent, for example in one or more of the core region, the intermediate layer or layers or the outer layer.
- the active agent in the body may be selected from pharmaceutical and/or cosmetic active agents, which may be selected from growth factors; growth factor receptors; transcriptional activators; translational promoters; antiproliferative agents; growth hormones; anti-rejection drugs; anti-thrombotic agents; anti-coagulants; stem cell or gene therapies; antioxidants; free radical scavengers; nutrients; co-enzymes; ligands; cell adhesion peptides; peptides; proteins; nucleic acids; DNA; RNA; sugars; saccharides; nutrients; hormones; antibodies; immunomodulating agents; growth factor inhibitors; growth factor receptor antagonists; transcriptional repressors; translational repressors; replication inhibitors; inhibitory antibodies; cytotoxin; hormonal agonists; hormonal antagonists; inhibitors of hormone biosynthesis and processing; antigestagens; antiandrogens; anti-inflammatory agents
- the layered body may comprise a diagnostic agent, for example in one or more of the core region, the intermediate layer or layers or the outer layer.
- the diagnostic agent in the body may be an agent suitable for use in a technique selected from, but not limited to, diagnostic medical imaging procedures (for example, radiographic imaging (x-ray), fluorescence spectroscopy, Forster/fluorescent resonance energy-transfer (FRET), computed tomography (CT scan), magnetic resonance imaging (MRI), positron emission tomography (PET), other nuclear imaging, and the like.
- the diagnostic agent may be an agent for use in diagnostic imaging, for example a contrast agents, such as barium sulfate for use with MRI, for example, or fluorescein isothiocyanate (FITC).
- At least one of the core region, the intermediate layer or layers, and the outer layer may comprise an active agent selected from a diagnostic agent and a therapeutic agent.
- the diagnostic agent may be selected from, for example, contrast agents, e.g. contrast agents for use in MRI techniques, and luminescent agents, e.g. fluorescent agents.
- the therapeutic agent may be a drug for the treatment or prevention of a disease.
- at least one or the core region, the intermediate layer or layers, and the outer layer may comprises an agent selected from a peptide, DNA and RNA.
- Suitable active agents for use in such pharmaceutically and/or cosmetically acceptable compositions are well known to those of skill in the art and include, by way of non-limiting example, those disclosed in the Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Thirteenth Edition (2001) by Merck Research Laboratories and the International Cosmetic Ingredient Dictionary and Handbook, Tenth Ed., 2004 by Cosmetic Toiletry and Fragrance Association, and U.S. Pat. Nos. 6,589,562, 6,825,161, 6,063,365, and 6,491,902, all to Shefer et al, each incorporated herein by reference.
- At least one of the core region, the intermediate layer or layers, and the outer layer may comprise a diagnostic agent and another of the core region, the intermediate layer or layers, and the outer layer comprises a therapeutic agent.
- the at least one dimension, measured across the body and through the core region, is 100 ⁇ m or less, optionally 50 ⁇ m or less, optionally 30 ⁇ m or less, optionally 20 ⁇ m or less, optionally 10 ⁇ m or less, optionally 1 ⁇ m or less, optionally 500 nm or less, optionally 200 nm or less.
- the dimension may be the diameter of the capsule, optionally the diameter of the capsule at its widest point.
- the body is in the form of a thread
- the dimension may be the diameter of the thread, optionally the diameter of the thread at its widest point.
- the measurement of the dimension may be made for example by obtaining an image of the body using a suitable means, such as scanning electron microscopy, and measuring the dimension across the body.
- the present invention provides an electrohydrodynamic device for producing one or more layered bodies
- the needles are able to be charged by applying a voltage to the needles.
- the needles are preferably made from an electrically conducting material, preferably a metal.
- the metal may be selected from, for example, an elemental metal or a metal alloy.
- the metal may, for example, comprise steel.
- the innermost needle in the device, which defines the hollow core may have an inner diameter of at least 0.01 mm, preferably at least 0.1 mm.
- the innermost needle in the device, which defines the hollow core may have an inner diameter of from 0.01 mm to 2 mm, optionally from 0.05 to 1.5 mm, optionally from 0.15 to 1.0 mm, optionally from 0.15 to 0.25 mm, optionally about 0.2 mm
- the space between the outer surface of a needle and the inner surface of the outwardly disposed adjacent needle may be from 0.01 mm to 1.5 mm, preferably 0.1 mm to 1 mm, optionally 0.2 to 0.9 mm, optionally 0.3 to 0.7 mm, optionally about 0.5 mm
- the space between the outer surface of each needle (except the outer needle) and the inner surface of the outwardly disposed adjacent needle may be from 0.01 mm to 1.5 mm, preferably 0.1 mm to 1 mm, optionally 0.2 to 0.9 mm, optionally 0.3 to 0.7 mm, optionally about 0.5 mm
- the device comprises an inner needle, which defines the hollow core, which has an inner diameter of from 0.15 to 1.0 mm, optionally from 0.15 to 0.25 mm, optionally about 0.2 mm, at least three needles disposed outwardly in a concentric manner from the innermost needle, wherein the space between the outer surface of each needle (except the outer needle) and the inner surface of the outwardly disposed adjacent needle is from 0.01 mm to 1.5 mm, preferably 0.1 mm to 1 mm, optionally 0.2 to 0.9 mm, optionally 0.3 to 0.7 mm, optionally about 0.5 mm
- the means for applying a voltage to the needles may apply any suitable voltage.
- the voltage may be from 1 kV to 50 kV, preferably 3 kV to 30 kV, more preferably 15 kV to 25 kV, optionally about 20 kV.
- the means for supplying a voltage may apply a dc voltage or an ac voltage.
- a ground electrode may be present, which may be at or near the collection means.
- the ground electrode is a ring electrode, which may be placed such that the centre of the ring is along the axis formed by the innermost needle.
- the ground electrode may be placed at any suitable distance from the needles, for example a distance of from 1 mm to 1 m, optionally 1 mm to 50 cm, optionally 1 mm to 10 cm, optionally 1 mm to 20 mm, optionally 5 mm to 15 mm, optionally about 12 mm
- the device optionally further comprises means for supplying a fluid to each channel.
- the means for supplying a fluid to each channel preferably can supply a fluid medium selected from the first and second fluid medium.
- at least one of the intermediate concentrically disposed channels is in fluid connection with a means for supplying the first fluid medium; and optionally the remaining channels are in fluid connection with a fluid medium selected from the first fluid medium and the second fluid medium.
- the means for supplying a fluid to each channel preferably comprises a syringe pump.
- a syringe pump is in fluid connection with one end of each channel.
- Each means for supplying a fluid can preferably supply a fluid medium at a rate of from 1 ⁇ l/min to 2000 ⁇ l/min, optionally from 50 to 1000 ⁇ l/min, optionally from 100 to 800 ⁇ l/min.
- the device further comprises a collection means for collecting the fluid mediums exiting the needles and/or the layered body or bodies formed therefrom.
- the collection means is preferably earthed.
- the collection means may be a receptacle.
- the device may further comprise a means for observing the fluid mediums exiting the needles and/or the layered body or bodies formed therefrom.
- the means for observing may comprise a camera, optionally connected to a recording means.
- the camera may optionally be connected to a visual display means, so that the fluid mediums exiting the needles and/or the layered body or bodies formed therefrom exiting the needles can be observed.
- the present invention provides a process for producing one or more layered bodies, the process
- an electrohydrodynamic device comprising at least three concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least one intermediate concentrically disposed tubular channel, and an outer concentrically disposed tubular channel,
- This method involves passing the first fluid medium through each of the plurality of channels disposed adjacent to the intermediate concentrically disposed tubular channel through which the second fluid medium is passed.
- the device comprises three concentrically arranged, spaced apart hollow needles, it has a core channel, a single intermediate concentrically disposed tubular channel, and an outer channel, with the core channel and the outer channel being disposed adjacent to the intermediate concentrically disposed tubular channel. Accordingly, if the device comprises three concentrically arranged, spaced apart hollow needles, the second fluid medium is passed through the intermediate concentrically disposed tubular channel, and the first fluid medium is passed through the core channel and the outer concentrically disposed tubular channel.
- the device of this aspect comprises at least four concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least two intermediate concentrically disposed tubular channel, and an outer concentrically disposed tubular channel, and the fluid medium passed through at least one of the at least two intermediate concentrically disposed tubular channels is the second fluid medium, and optionally the fluid medium passed through the core channel is the second fluid medium.
- the present invention provides a process for producing one or more layered bodies, the process comprising:
- the fluid mediums may be selected from a first fluid medium comprising a liquid comprising a non-volatile component and a second fluid medium comprising or consisting of a volatile liquid.
- the processes of the fourth or fifth aspect may be electrohydrodynamic processes. As the fluid mediums leave the needles, typically a jet of the fluid mediums is formed, which then either breaks up into capsules or remains intact to produce a thread.
- the first fluid medium comprises a liquid comprising a non-volatile component.
- the liquid of the first fluid medium may be the non-volatile component.
- the liquid may have a boiling point of at least 100° C., optionally at least 150° C., optionally at least 200° C., optionally at least 250° C. All boiling and melting points given herein, unless otherwise stated, are measured at standard pressure (101.325 kPa).
- the liquid may comprise an organic solvent.
- the organic solvent may comprise a non-polar solvent and/or a polar solvent.
- the organic solvent may comprise an aprotic solvent and/or a protic solvent.
- Non-polar solvents include, but are not limited to, pentane, cyclopentane, hexane, benzene, toluene, 1,4-dioxane, chloroform, and diethylether.
- the solvent may comprise a polar aprotic solvent, optionally selected from dichloromethane, tetrahydrofuran, ethylacetate, acetone, dimethylformamide, acetonitrile, dimethyl sulphoxide.
- the solvent may comprise a polar protic solvent, optionally selected from formic acid, n-butanol, isopropanol, n-propanol, ethanol, methanol and acetic acid.
- the organic solvent may comprise a hydrocarbon.
- the hydrocarbon may comprise an aromatic or an aliphatic hydrocarbon.
- the hydrocarbons may be selected from, but are not limited to, pentane, cyclopentane, hexane, cyclo
- the first fluid medium preferably has a dynamic viscosity of 1.5 mPas or more, optionally a dynamic viscosity of 1.6 mPas or more, optionally a dynamic viscosity of 1.7 mPas or more.
- the dynamic viscosity is measured at standard temperature (25° C.) and pressure (101.325 kPa).
- the dynamic viscosity of the first fluid medium is preferably more than the dynamic viscosity of the second fluid medium, when measured under the same conditions.
- Dynamic viscosity values can be measured according to a standard method known to those skilled in the art, for example by using a U-tube viscometer or a rotational viscometer, such as a commercially available VISCOEASY rotational viscometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- the first fluid medium preferably has a surface tension of 20 mNm ⁇ 1 or more, optionally 25 mNm ⁇ 1 or more, optionally 30 mNm ⁇ 1 or more.
- the first fluid medium preferably has a surface tension of 20 mNm ⁇ 1 to 30 mNm ⁇ 1 .
- the surface tension of the first fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa).
- the surface tension of the first fluid medium is preferably more than the surface tension of the second fluid medium, when measured under the same conditions.
- Surface tension can be measured according to a standard method known to those skilled in the art, for example by using a tensiometer, e.g. a commercially available Kruss Tensiometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- the conductivity of the first fluid medium is preferably 1 ⁇ 10 ⁇ 8 Sm ⁇ 1 or more, optionally 1 ⁇ 10 ⁇ 7 Sm ⁇ 1 more, optionally 1 ⁇ 10 ⁇ 6 Sm ⁇ 1 or more, optionally 1 ⁇ 10 ⁇ 5 Sm ⁇ 1 or more.
- Conductivity in this context refers to the electrical conductivity.
- the conductivity of the first fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa).
- the conductivity of the first fluid medium is preferably more than the conductivity of the second fluid medium, when measured under the same conditions.
- Conductivity can be measured according to a standard method known to those skilled in the art, for example by using a conductivity probe, such as the commercially available HI-8733 conductivity probe, available from Sigma-Aldrich. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- the liquid of the first fluid medium may be any suitable liquid in which a non-volatile component, e.g. a polymer, can be dissolved and/or suspended.
- the non-volatile component e.g. a polymer
- the non-volatile component may be completely dissolved in the liquid of the first fluid medium.
- the non-volatile component may be an organic substance, optionally a polymer.
- the non-volatile component preferably has a melting point of at least 100° C., optionally at least 150° C., optionally at least 200° C., optionally at least 250° C.
- the non-volatile component preferably comprises a polymer.
- the non-volatile component e.g.
- a polymer may be present in the liquid of the first fluid medium in an amount of at least 1% by weight, preferably at least 10% by weight, optionally at least 20% by weight, optionally at least 40% by weight, optionally at least 50% by weight, optionally at least 60% by weight, optionally at least 70% by weight, optionally at least 80% by weight. It has been found that if at least one of the fluid mediums comprises at least 60% by weight of a polymer, particularly the fluid medium passed down the outer concentrically disposed channel, the formation of a layered body in the form of a thread is promoted.
- At least one of the fluid mediums comprises less than 60% by weight of a polymer, particularly the fluid medium passed down the outer concentrically disposed channel, the formation of layered bodies in the form of capsules is promoted. Accordingly, in an embodiment, at least one of the fluid mediums, optionally the fluid medium passed down the outer concentrically disposed channel, comprises a polymer in an amount of 60% by weight or more. Accordingly, in an embodiment, at least one of the fluid mediums, optionally the fluid medium passed down the outer concentrically disposed channel, comprises a polymer in an amount of less than 60% by weight.
- Particularly preferred polymers for use in the first fluid medium include, but are not limited to sodium polystyrene sulfonate (PSS), polyethers, such as a polyethylene oxide (PEO), polyoxyethylene glycol or polyethylene glycol (PEG), polyethylene imine (PEI), a biodegradable polymer such as a polylactic acid, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) (PLGA), polymethylsilsesquioxane (PMSQ) and copolymers, derivatives, and mixtures thereof.
- PPS sodium polystyrene sulfonate
- PES polyethers
- PEO polyethylene oxide
- PEG polyoxyethylene glycol or polyethylene glycol
- PEI polyethylene imine
- a biodegradable polymer such as a polylactic acid, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) (PLGA), polymethylsilsesquio
- the polymer for use in the first fluid medium may have a property selected from: being positively-charged being (cationic), being negatively-charged (anionic), being polyethylene glycol(PEG)-ylated, being covered with a zwitterion, being hydrophobic, being superhydrophobic (for example having with water contact angles in excess of 150°), being hydrophilic, being superhydrophilic (for example, where the water contact angle is near or at 0°), being olephobic/lipophobic, being olephilic/lipophilic, and/or nanostructured, among others.
- the polymer for use in the first fluid medium may be a water-soluble and/or hydrophilic polymers, which may be selected from biocompatible polymers, including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and mixtures thereof.
- biocompatible polymers including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and mixtures thereof.
- biocompatible polymers including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl
- the polymer for use in the first fluid medium may also be selected from polyvinylpyrrolidone, vinyl acetate, polyvinylpyrrolidone-vinyl acetate copolymers, polyvinyl alcohol (PVA), acrylates and polyacrylic acid (PAA), including polyacrylate polymer, vinylcaprolactam/sodium acrylate polymers, methacrylates, poly(acryl amide-co-acrylic acid) (PAAm-co-AA), vinyl acetate and crotonic acid copolymers, polyacrylamide, polyethylene phosphonate, polybutene phosphonate, polystyrene, polyvinylphosphonates, polyalkylenes, and carboxy vinyl polymer.
- the multiphasic fiber compositions may comprise derivatives, copolymers, and further combinations of such polymers, as well.
- the polymer for use in the first fluid medium may be selected from water insoluble or hydrophobic polymers including, but not limited to, cellulose acetate, cellulose nitrate, ethylene-vinyl acetate copolymers, vinyl acetate homopolymer, ethyl cellulose, butyl cellulose, isopropyl cellulose, shellac, hydrophobic silicone polymer (e.g., dimethylsilicone), polymethyl methacrylate (PMMA), cellulose acetate phthalate and natural or synthetic rubber; siloxanes, such as polydimethylsiloxane (PMDS), cellulose, polyethylene, polypropylene, polyesters, polyurethane and nylon, including copolymers, derivatives, and combinations thereof.
- water insoluble or hydrophobic polymers including, but not limited to, cellulose acetate, cellulose nitrate, ethylene-vinyl acetate copolymers, vinyl acetate homopolymer, ethyl cellulose, butyl
- the polymers for use in the first fluid medium may be crosslinked, optionally after formation of the body, for example by the application of heat, ionizing radiation or other methods of curing and treating polymers known to those of skill in the art.
- the polymer for use in the first fluid medium may be selected from sodium alginate, carrageenan, xanthan gum, gum acacia, Arabic gum, guar gum, pullulan, agar, chitin, chitosan, pectin, karaya gum, locust bean gum, various polysaccharides; starches such as maltodextrin, amylose, corn starch, potato starch, rice starch, tapioca starch, pea starch, sweet potato starch, barley starch, wheat starch, modified starch (e.g., hydroxypropylated high amylose starch), dextrin, levan, elsinan and gluten; and proteins such as collagen, whey protein isolate, casein, milk protein, soy protein, keratin, and gelatin.
- starches such as maltodextrin, amylose, corn starch, potato starch, rice starch, tapioca starch, pea starch, sweet potato starch,
- first fluid medium as described herein, is passed through two adjacent channels, preferably, the first fluid mediums in one of these channels is immiscible with the first fluid medium in the adjacent channel.
- the first fluid mediums should be sufficiently immiscible such that two distinct phases form in the layered bodies. A person skilled in the art of electrohydrodynamic techniques could select appropriate first fluid mediums.
- the second fluid medium comprises or consists of a volatile liquid.
- the volatile liquid is a liquid that has a boiling point not higher than 50° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels, optionally not higher than 40° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels, optionally not higher than 35° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels, optionally not higher than 30° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels.
- the volatile liquid has a boiling point of 75° C. or less.
- the volatile liquid may have a boiling point of less than 100° C., optionally less than 80° C., optionally less than 70° C., optionally less than 60° C., optionally less than 50° C.
- the temperature of the environment into which the fluid mediums pass into when exiting the channels may be any suitable temperature.
- the process may be carried out such that the temperature of the environment into which the fluid mediums pass into when exiting the channels is at or above the boiling point of the liquid of the second fluid medium.
- the temperature of the environment into which the fluid mediums pass into when exiting the channels may be above 15° C., optionally above 20° C., optionally above 25° C.
- the temperature of the environment into which the fluid mediums pass into when exiting the channels may be less than 150° C., optionally less than 100° C., optionally less than 80° C., optionally less than 60° C., optionally less than 40° C.
- the temperature of the environment into which the fluid mediums pass into when exiting the channels may be from 10 to 40° C., optionally from 20 to 30° C. It has been surprisingly found that when a second fluid medium as described herein is passed down the intermediate channel (with the first fluid medium being passed down the other channels as described herein), a layered body is formed that has a intermediate layer comprising a gas.
- the environment into which the fluid mediums pass into when exiting the channels may or may not contain a gas.
- the environment into which the fluid mediums pass into when exiting the channels contains a gas, which may comprise a gas selected from nitrogen, oxygen, and a gas from Group 18 of the periodic table.
- the gas from Group 18 of the periodic table may be selected from helium, neon and argon.
- the environment into which the fluid mediums pass into when exiting the channels may contain air.
- the environment into which the fluid mediums pass into when exiting the channels may contain a gas and be at a pressure of from 80 kPa to 120 kPa, optionally 90 to 110 kPa, optionally 95 to 105 kPa, optionally around standard pressure (101.325 kPa).
- the volatile liquid may be selected from a non-polar liquid, a polar aprotic liquid, and polar protic solvents.
- the volatile liquid comprises or is a perhalocarbon, most preferably a perfluorocarbon.
- Perhalocarbons are organic compounds consisting of carbon and halogen atoms.
- Perfluorocarbons are organic compounds consisting of carbon and fluorine atoms.
- the perhalocarbon e.g. the perfluorocarbon, contains 10 carbon atoms or less, optionally 9 carbons atoms or less, optionally 8 carbons atoms or less, optionally 7 carbons or less, optionally 6 carbons or less, optionally 5 carbons or less, optionally 4 carbons or less.
- the perhalocarbon e.g. the perfluorocarbon
- the perfluorocarbon may be selected from, but is not limited to, octafluoropropane, perfluorohexane, perfluoropentane, and perfluorodecalin.
- the volatile liquid may comprise a halogenated hydrocarbon, which may be selected from, but is not limited to, a halogenated alkane, halogenated alkene and halogenated alkyne.
- the hydrocarbon may be branched or linear, and optionally substituted with one or more substituents other than a halogen.
- the halogenated hydrocarbon may have one or more halogens on each molecule, which may be selected from fluorine, chlorine, bromine and iodine.
- the halogenated hydrocarbon is preferably a fluoroalkyl.
- the halogenated hydrocarbon may contain 10 carbons or less, optionally 9 carbons atoms or less, optionally 8 carbons atoms or less, optionally 7 carbons or less, optionally 6 carbons or less, optionally 5 carbons or less, optionally 4 carbons or less.
- the halogenated hydrocarbon may contain 3 or more carbon atoms, optionally 4 or more carbon atoms.
- the volatile liquid comprises a heterofluoroalkyl.
- heterofluoroalkyls include, but are not limited to, methoxynonafluorobutane and ethoxynonofluorobutane.
- the volatile solvent may comprise an organic solvent selected from, but not limited to, ethanol, acetone, ethyl acetate, acetates, alcohol, ether, aliphatic, aromatic hydrocarbons, chlorinated hydrocarbons, ketones and chloroform.
- the second fluid medium preferably has a dynamic viscosity of 1.3 mPas or less, optionally a dynamic viscosity of 1.2 mPas or less, optionally a dynamic viscosity of 1.1 mPas or less.
- the dynamic viscosity is measured at standard temperature (25° C.) and pressure (101.325 kPa).
- Dynamic viscosity values can be measured according to a standard method known to those skilled in the art, for example by using a U-tube viscometer or a rotational viscometer, such as a commercially available VISCOEASY rotational viscometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- the second fluid medium preferably has a surface tension of 20 mNm ⁇ 1 or less, optionally 18 mNm ⁇ 1 or less, optionally 15 mNm ⁇ 1 or less, optionally 12 mNm ⁇ 1 or less.
- the surface tension of the second fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa). Surface tension can be measured according to a standard method known to those skilled in the art, for example by using a tensiometer, e.g. a commercially available Kruss Tensiometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- the conductivity of the second fluid medium is preferably 1 ⁇ 10 ⁇ 8 Sm ⁇ 1 or less, optionally 1 ⁇ 10 ⁇ 9 Sm ⁇ 1 or less, optionally 1 ⁇ 10 ⁇ 10 Sm ⁇ 1 or less, optionally 1 ⁇ 10 ⁇ 11 Sm ⁇ 1 or less.
- the conductivity of the second fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa). Conductivity can be measured according to a standard method known to those skilled in the art, for example by using a conductivity probe, such as the commercially available HI-8733 conductivity probe, available from Sigma-Aldrich. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- the first and second fluid mediums are immiscible.
- the volatile liquid has a solubility in the liquid of the first fluid medium of 100 ppm or less, optionally 50 ppm or less, optionally 20 ppm or less, measured at standard temperature (25° C.) and pressure (101.325 kPa).
- the first fluid medium comprises a non-halogenated organic solvent and the second fluid medium comprises a perhalocarbon and/or a halogenated hydrocarbon.
- the first fluid medium comprises a non-halogenated organic solvent and the second fluid medium comprises a perfluorocarbon and/or a halogenated hydrocarbon having one or more fluorines on each molecule.
- the non-halogenated organic solvent may be selected from, but is not limited to, an aprotic solvent and a protic solvent.
- the non-halogenated organic solvent may be selected from ethanol, acetone, ethyl acetate, acetates, alcohol, ether, aliphatic, aromatic hydrocarbons, chlorinated hydrocarbons, ketones and chloroform.
- the first fluid medium comprises a non-halogenated organic solvent and a polymer
- the second fluid medium comprises a perfluorocarbon and/or a halogenated hydrocarbon.
- One or more of the fluid mediums passed down the channels may comprise one or more pharmaceutically acceptable substances.
- All of the fluid mediums passed down the channels are pharmaceutically acceptable substances.
- the pharmaceutically acceptable substances may be carrier substances, suitable for acting as carriers for one or more agents selected from diagnostic and therapeutic agents.
- the carrier species may be an organic substance, optionally a polymeric substance.
- the carrier species is preferably a biocompatible carrier species.
- the carrier species may be selected from poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polymethylsilsesquioxane (PMSQ), perfluorohexane (PFH), perfluoropentane (PFP), polyurethane, starch, albumin, polyethylene oxide (PEO), glycerol and oil, such as olive oil.
- PLGA poly(lactic-co-glycolic acid)
- PCL polycaprolactone
- PMSQ polymethylsilsesquioxane
- PH perfluorohexane
- PFP perfluoropentane
- polyurethane starch
- albumin polyethylene oxide
- PEO polyethylene oxide
- glycerol such as olive oil.
- the one or more fluid mediums may comprise a liquid having a pharmaceutically acceptable substance, e.g. the carrier substance, therapeutic agent and/or diagnostic agent as described herein, dispersed therein, e.g. dissolved therein or suspended therein.
- the liquid may comprise a polar or non-polar solvent.
- the liquid may comprise a protic or non-protic solvent.
- the liquid in the fluid medium may, for example, be as described above.
- the rate of passing the fluid mediums through the device may be any suitable rate.
- the rates may be varied according to the nature of the fluid medium, and the desired type of layered bodies to be formed.
- the rate of passing the fluid mediums through the device may be, for each fluid medium being passed through each channel, from 1 ⁇ l/min to 2000 ⁇ l/min, optionally from 50 to 1000 ⁇ l/min, optionally from 100 to 800 ⁇ l/min.
- FIGS. 1, 2 and 3 shows an embodiment of the electrohydrodynamic device of the present invention.
- the device comprises four concentrically arranged, spaced apart hollow needles A, B, C and D, the needles together defining a core channel W, two intermediate concentrically disposed tubular channels X and Y, and an outer concentrically disposed tubular channel Z; and a means for applying a voltage to the needles.
- a syringe pump is fluidly connected to one end of each channel.
- the inner surface of the innermost needle A defines the core channel W.
- the core channel W is fluidly connected to syringe 1, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone.
- the outwardly disposed adjacent needle to the core needle is intermediate needle B.
- An intermediate concentrically disposed tubular channel X is defined by the outer surface of innermost needle A and inner surface of needle B.
- Tubular channel X is fluidly connected to syringe 2, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone.
- the outwardly disposed adjacent needle to intermediate needle B is intermediate needle C.
- An intermediate concentrically disposed tubular channel Y is defined by the outer surface of needle B and inner surface of needle C.
- Tubular channel Y is fluidly connected to syringe 3, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone.
- the outwardly disposed adjacent needle to intermediate needle C is outermost needle D.
- An outer concentrically disposed tubular channel Z is defined by the outer surface of innermost needle C and inner surface of needle D.
- Tubular channel Z is fluidly connected to syringe 4, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone.
- each of needles A, B and C is in flush connection with the adjacent outwardly disposed needle.
- FIG. 2B shows a cross-sectional view of the needles and the channels they define along the line A-A of FIG. 2A .
- FIG. 2B shows the dimensions of a particular embodiment of the needles, as used in the Examples below. These dimensions can be varied and may be otherwise as described herein, depending on the desired size of the particles or threads that the skilled person wishes to produce with the device.
- ID and OD represent, respectively, inner diameter and outer diameter.
- the needles may be orientated so that the axis of the needles is substantially vertical.
- a collection means is provided for collecting the layered body or bodies formed from the fluid composition after exiting the needles.
- the collection means is earthed.
- the collection means is disposed below the needles.
- the collection means may be in any suitable form, for example a plate or a receptacle.
- FIGS. 3A and 3B show photographs of the needles used in the electrohydrodynamic system of FIGS. 1 and 2 , with FIG. 3A showing the separate needles, and FIG. 3B showing the needles assembled.
- the left hand needle is needle A, with needles B, C and D shown in order to the right.
- syringe 1 can provide a liquid 1 to channel W, preferably a second fluid medium as described herein.
- syringe 2 can provide a liquid 2 to channel X, preferably a first fluid medium as described herein.
- syringe 3 can provide a liquid 3 to channel Y, preferably a second fluid medium as described herein.
- syringe 4 can provide a liquid 4 to channel Z, preferably a first fluid medium as described herein.
- Each of the syringes preferably supplies a fluid medium, e.g. the first or second fluid medium as described herein, at a suitable rate, e.g.
- the rate of supply of the fluid medium for each channel may be the same as or different to one or more of the other channels, e.g. the adjacent channel disposed outwardly or inwardly.
- FIGS. 4A to 4D show embodiments of the layered bodies of the present invention.
- the layered bodies are in the form of a capsule.
- the layered body is in the form of a thread.
- the layered body in FIG. 4A is in the form of a capsule and comprises: a core region R C ; two intermediate layers, R I1 and R I2 , disposed around, e.g. concentrically around, the core region; an outer layer R O disposed around, e.g. concentrically around, the two intermediate layers.
- the diameter of the capsule is typically 100 ⁇ m or less.
- the core region is substantially spherical.
- the intermediate layers and the outer layer are in the form of approximate spheres.
- the core region R C is in the form an approximately spherical particle having a coating of intermediate layer R I1 surrounding the particle.
- the core region, the intermediate layers R I1 and R I2 , and the outer layer R O all comprise liquid or solid materials.
- the body shown in FIG. 4A may be produced using the device shown in FIGS. 1 to 3B .
- the first fluid medium is passed down each of the four channels and an appropriate voltage applied to the needles, such that, when the fluid mediums exit the needles, they form a jet that breaks up into droplets, the droplets being in the form of the capsule shown in FIG. 4A .
- the droplets are collected on or in the earthed collecting means.
- the layered body in FIG. 4B is in the form of a capsule and comprises: a core region R C ; two intermediate layers, R I1 and R I2 disposed around, e.g. concentrically around, the core region; an outer layer R O disposed around, e.g. concentrically around, the two intermediate layers.
- the diameter of the capsule is typically 100 ⁇ m or less.
- the core region is substantially spherical.
- the intermediate layers and the outer layer are in the form of approximate spheres.
- the core region R C is in the form an approximately spherical particle having a coating of intermediate layer R I1 surrounding the particle.
- the core region, the intermediate layers R I1 , and the outer layer R O all comprise liquid or solid materials.
- the intermediate layer R I2 is a substantially hollow region comprising a gas, for example air.
- a gas for example air.
- FIG. 4B may be produced using the device shown in FIGS. 1 to 3B .
- the first fluid medium as described herein is passed down each of the channels W, X and Z
- a second fluid medium as described herein is passed down channel Y and an appropriate voltage applied to the needles, such that, when the fluid mediums exit the needles, they form a jet that breaks up into droplets, the droplets being in the form of the capsule shown in FIG. 4B .
- the droplets are collected on or in the earthed collecting means.
- the core and intermediate layers may alter positions to a small extent, such that the core region R C and surrounding intermediate layer R I1 shift, e.g. due to gravity, within the gas-containing layer R I2 , such that the layer intermediate layer R I1 is in contact with the outer layer R O .
- This is shown in FIG. 8 .
- the layered body of FIG. 8 is nevertheless encompassed by the first and second aspects of the invention.
- the layered body in FIG. 4C is in the form of a capsule and comprises: a core region R C ; two intermediate layers, R I1 and R I2 disposed around, e.g. concentrically around, the core region; an outer layer R O disposed around, e.g. concentrically around, the two intermediate layers.
- the diameter of the capsule is typically 100 ⁇ m or less.
- the core region is substantially spherical.
- the intermediate layers and the outer layer are in the form of approximate spheres.
- the intermediate layer R I1 , and the outer layer R O all comprise liquid or solid materials.
- the core region R O and the intermediate layer R I2 are substantially hollow regions comprising a gas, for example air.
- the body shown in FIG. 4C may be produced using the device shown in FIGS. 1 to 3B .
- the first fluid medium as described herein is passed down each of the channels X and Z
- the second fluid medium as described herein is passed down channels W and Y and an appropriate voltage applied to the needles, such that, when the fluid mediums exit the needles, they form a jet that breaks up into droplets, the droplets being in the form of the capsule shown in FIG. 4C .
- the droplets are collected on or in the earthed collecting means.
- the core and intermediate layers may alter positions to a small extent, such that the core region R C and surrounding intermediate layer R I1 shift, e.g.
- FIG. 9 The layered body of FIG. 9 is nevertheless encompassed by the first and second aspects of the invention.
- the layered body in FIG. 4D is in the form of a thread and comprises: a core region; two intermediate layers, disposed around, e.g. concentrically around, the core region; an outer layer disposed around, e.g. concentrically around, the two intermediate layers.
- the core is elongated and has an axis, and the two intermediate layers and the outer layer are disposed around, e.g. concentrically around, the axis.
- the core forms a substantially cylindrical core.
- the two intermediate layers and the outer layer are also in the form of approximate cylinders.
- the content of the core region, intermediate layers and the outer layer of the thread may be as described for the particles shown in FIGS. 4A, 4B and 4C .
- Threads according to FIG. 4D may be produced using the device shown in FIGS. 1 to 3B . It has been found that the formation of a threads can be promoted by dissolving or suspending a suitable material in a fluid medium in an appropriate concentration, this fluid medium being passed down one of the channels of the device. For example, threads have been found to be promoted if at least one of the fluid mediums being passed down the channels contains a polymeric material in an amount of 60% or more by weight. For example, threads have been found to be promoted if at least one of the fluid mediums being passed down the channels contains a non-polymeric material in an amount of 50% or more by weight.
- the present invention further provides a composition comprising a plurality of bodies of the first aspect and/or a plurality of bodies of the second aspect.
- the plurality of bodies may contain a collection of bodies all according to the first aspect or the second aspect, but nevertheless having differing characteristics, for example being of different diameters and/or having different compositions.
- the present invention further provides a plurality of bodies obtainable by a method according to the fourth aspect and/or a method according to the fifth aspect.
- the plurality of bodies may contain a collection of bodies all obtainable by a method according to the fourth aspect and/or a method according to the fifth aspect, but nevertheless having differing characteristics, for example being of different diameters and/or having different compositions.
- the four-needle electrohydrodynamic device used in the Examples was as shown in FIGS. 1 to 3B , and as described above.
- the dimensions of the needles was as shown in FIG. 2B , and the connectivity of each needle and channel as shown in FIGS. 1 and 2A .
- the flow rates of fluid mediums supplied to the channels were controlled by four high-precision programmable syringe pumps (available from Harvard PHD 4400, Apparatus, Edenbridge, UK), labelled Syringe 1, 2, 3 and 4 in FIG. 1 .
- the distance from the exit of the outer needle to the ground electrode was fixed at 12 mm in all the experiments.
- the flow of the liquids under the influence of the electric field was visualized using a video camera (LEICA S6D JVC-colour).
- the perfluorohexane represents an example of a second fluid medium as described herein.
- the ethanol containing 18 wt % of PMSQ represents an example of a first fluid medium as described herein.
- ethanol was used as the calibrating medium in the relevant measurement equipment used.
- the density of each fluid medium was measured using a standard 25 ml density bottle.
- the surface tension values of each fluid medium were measured using a Kruss Tensiometer. Viscosity values were determined using a U-tube viscometer and a VISCOEASY rotational viscometer. Electrical conductivity values were estimated using a HI-8733 conductivity probe.
- the syringe 1 of the device was loaded with the compound PFH (perfluorohexane), obtained from F2 Chemicals Ltd. This was supplied to channel W at a rate of 300 ⁇ l per minute.
- PFH perfluorohexane
- Syringe 2 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ), obtained from Wacker Chemie AG, GmbH. This was supplied to channel X at a rate of 600 ⁇ l per minute.
- PMSQ polymer polymethylsilsesquioxane
- Syringe 3 was loaded with PFH. This was supplied to channel Y at a rate of 300 ⁇ l per minute.
- Syringe 4 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ). This was supplied to channel Z at a rate of 600 ⁇ l per minute.
- PMSQ polymer polymethylsilsesquioxane
- the voltage applied to the needles was 20 kV.
- a jet was found to form, which broke up to form droplets or capsules, i.e. an embodiment of the layered bodies of the invention. It is considered that the cross section of the capsules may be represented schematically by FIG. 4C .
- a collection of the capsules is shown in FIG. 5 .
- Scanning electron microscopy (SEM, JEOL JSM-6301F field emission scanning electron microscope) was used to obtain this image and study the size of the as-formed products. 200 microspheres were analyzed from the SEM images to calculate the mean diameter of the capsules, this mean being the number mean.
- the mean diameter of the capsules was found to be 510 nm.
- the maximum diameter of the capsules was found to be 1350 nm.
- the minimum diameter of the capsules was found to be 35 nm.
- the syringe 1 of the device was loaded with the compound PFH (perfluorohexane), obtained from F2 Chemicals Ltd. This was supplied to channel W at a rate of 300 ⁇ l per minute.
- PFH perfluorohexane
- Syringe 2 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ), obtained from Wacker Chemie AG, GmbH. This was supplied to channel X at a rate of 300 ⁇ l per minute.
- PMSQ polymer polymethylsilsesquioxane
- Syringe 3 was loaded with PFH. This was supplied to channel Y at a rate of 300 ⁇ l per minute.
- Syringe 4 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ). This was supplied to channel Z at a rate of 300 ⁇ l per minute.
- PMSQ polymer polymethylsilsesquioxane
- the voltage applied to the needles was 20 kV.
- a jet was found to form, which broke up to form droplets or capsules, i.e. an embodiment of the layered bodies according to the invention. It is considered that the cross section of the capsules may be represented schematically by FIG. 4C .
- a collection of the capsules is shown in FIG. 6 .
- Scanning electron microscopy (SEM, JEOL JSM-6301F field emission scanning electron microscope) was used to obtain this image and study the size of the as-formed products. 200 microspheres were analyzed from the SEM images to calculate the mean diameter of the capsules, this mean being the number mean.
- the mean diameter of the capsules was found to be 590 nm.
- the maximum diameter of the capsules was found to be 1062 nm.
- the maximum diameter of the capsules was found to be 233 nm.
Abstract
Description
- This is a divisional application of U.S. application Ser. No. 13/984,345, filed under 35 U.S.C. § 371 on Oct. 14, 2013, published; which is the national stage entry of international application PCT/GB2012/050276, filed under the authority of the Patent Cooperation Treaty on Feb. 8, 2012, published; which claims priority to United Kingdom Application No. 1102148.2, filed on Feb. 8, 2011. The entire disclosures of all the aforementioned applications are expressly incorporated herein by reference for all purposes.
- The present invention relates to layered bodies, which may be in capsule or thread form, that typically have a size in the micro- or nanometer scale.
- Micro- or nanometre scale multilayer particles, capsules and fibres are of increasing interest in a number of fields, including diagnostic and therapeutic applications. They can be used, for example, to deliver therapeutic agents, contrast agents, living cells, and other species to desired sites in vivo. Because of their small size, it is a considerable challenge to create the micro- or nanometre scale multilayer particles, capsules and fibres with specific properties. Some methods of manufacturing the micro- or nanoscale species, while appearing initially promising, have suffered from their requirement to use surfactants or certain additives. It would be desirable to produce micro- or nanometer scale multilayer particles, capsules and fibres without surfactants or potentially harmful additives.
- One of the desirable uses of the micro- or nanometer scale multilayer capsules and fibres is as carriers for a specific agent, e.g. a therapeutic or diagnostic agent. Conventional carriers, e.g. those used in macroscale drug delivery applications, are limited in their performance for a number of reasons, and may not be suitable for use in the techniques for making the micro- or nanometer scale multilayer particles, capsules and fibres. Layer by layer deposition commonly requires selecting appropriate materials for adjacent layers so that they interact and adhere to one another, e.g. having adjacent layers comprising species of opposing charges or adjacent layers that rely on hydrogen bonding. Layer by layer deposition techniques are described, for example, in US 2005/0208100 and US 2005/0163714, both of which are incorporated herein by reference in their entirety. A drawback of layer by layer deposition is the considerable time it takes to produce the multilayered species, and the required use of certain material to produce the adherence between adjacent layers. Additionally, they typically use a crystalline material as a core, which leads to a non-spherical core in the final multilayered species.
- Recent developments in producing micro- or nanometer scale multilayer capsules and fibres have been through the use of electrohydrodynamic processes. An example of such a process is described in J. R. Soc. Interface (2008) 5, 1255-1261, authored by Ahmad et al., which is incorporated herein by reference in its entirety. Such processes typically use a flowing medium that is subjected to an applied electric field. The process can result in a formation of a jet, which then breaks up into fine droplets or remains intact to produce a fibre or thread. The paper authored by Ahmad et al., mentioned above, describes an electrohydrodynamic process that employs three concentric needles. The needles typically have a diameter that is far larger (e.g. larger than 0.1 mm) than the capsules or fibres they can produce (having diameters in the micrometer and/or nanometer scale). While the process of Ahmed et al offered advantages over the prior art, it was limited in the types of multilayered structures it can produce.
- Hollow particles of the micro or nanometer scale, sometimes termed microbubbles, have also been found useful in certain applications. They are sometimes used as contrast agents in ultrasound. Recent investigations have been made into the use of microbubbles for the treatment and assessment of cancer. This is achieved by loading a desired agent on the surface of the bubble or cavity, which collapses with the application of ultra-sound at the desired site, enabling site-specific release of the agent.
- It would be desirable to provide alternative methods and products to those described in the prior art, ideally methods and products that overcome or mitigate at least one problem associated with the prior art, whether or not expressly mentioned herein.
- In a first aspect, the present invention provides a layered body comprising:
- a core region;
- at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer,
- wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 μm or less. In an embodiment, the layered body may be in the form of a capsule. In an embodiment, the layered body may be in the form of a thread. In the present context, “intermediate” indicates that a layer is disposed between the core region and the outer layer. The outer layer will typically encompass the whole of the core region, at least in a cross section of the body, and the intermediate layer or layers will be disposed between the outer layer and the core region
- In a second aspect, the present invention provides a layered body comprising:
- a core region having a substantially circular cross section;
- at least two intermediate layers disposed around the core region;
- an outer layer disposed around the at least two intermediate layers, the layered body having at least one dimension, measured across the body and through the core region, of 100 μm or less. In an embodiment, the layered body may be in the form of a capsule. In an embodiment, the layered body may be in the form of a thread. In the present context, “intermediate” indicates that a layer is disposed between the core region and the outer layer. The outer layer will typically encompass the whole of the core region, at least in a cross section of the body, and the intermediate layer or layers will be disposed between the outer layer and the core region. “Substantially circular” can include a circular shape and non-circular shapes, such as an oval shape.
- In a third aspect, the present invention provides an electrohydrodynamic device for producing one or more layered bodies,
- the device comprising
- at least four concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least two intermediate concentrically disposed tubular channels, and an outer concentrically disposed tubular channel; and
- a means for applying a voltage to the needles. In the present context, “intermediate” indicates that a channel is disposed concentrically between the core channel and the outer channel. “Concentrically”, in the present context, indicates that intermediate channels surround the core channel and, in turn, the outer channel surrounds the intermediate channels; in an embodiment, all the channels may share the same geometric centre or axis, but this need not necessarily be the case.
- In a fourth aspect, the present invention provides a process for producing one or more layered bodies, the process
- comprising:
- providing an electrohydrodynamic device, the device comprising at least three concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least one intermediate concentrically disposed tubular channel, and an outer concentrically disposed tubular channel,
- providing a first fluid medium comprising a liquid comprising a non-volatile component
- providing a second fluid medium comprising or consisting of a volatile liquid,
- passing the second fluid medium through an intermediate concentrically disposed tubular channel, and, at the same time,
- passing the first fluid medium through each of the plurality of channels disposed adjacent to the intermediate concentrically disposed tubular channel through which the second fluid medium is passed,
- and applying a voltage to the needles,
- such that, on leaving the needles, one or more layered bodies is or are formed. The one or more layered bodies may be bodies according to the first aspect. In an embodiment, the device of this aspect comprises at least four concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least two intermediate concentrically disposed tubular channels, and an outer concentrically disposed tubular channel, and the fluid medium passed through at least one of the at least two intermediate concentrically disposed tubular channels is the second fluid medium, and optionally the fluid medium passed through the core channel is the second fluid medium; and optionally the fluid medium passed through the remaining channels is selected from the first fluid medium and the second fluid medium and is preferably the first fluid medium. In the present context, “intermediate” indicates that a channel is disposed concentrically between the core channel and the outer channel. “Concentrically”, in the present context, indicates that intermediate channels surround the core channel and, in turn, the outer channel surrounds the intermediate channels; in an embodiment, all the channels may share the same geometric centre or axis, but this need not necessarily be the case. The present invention further provides a layered body obtainable by the process according to the fourth aspect.
- In a fifth aspect, the present invention provides a process for producing one or more layered bodies, the process comprising:
- providing the electrohydrodynamic device according to the third aspect,
- passing fluid mediums through the hollow core, the at least two intermediate concentrically disposed tubular channels, and the outer concentrically disposed tubular channel,
- and applying a voltage to the needles,
- such that, on leaving the needles, one or more layered bodies is or are formed. The one or more layered bodies may be one or more layered bodies according to the second aspect. In the present context, “intermediate” indicates that a channel is disposed concentrically between the core channel and the outer channel. The fluid mediums may be selected from a first fluid medium comprising a liquid comprising a non-volatile component and a second fluid medium comprising or consisting of a volatile liquid. “Concentrically”, in the present context, indicates that intermediate channels surround the core channel and, in turn, the outer channel surrounds the intermediate channels; in an embodiment, all the channels may share the same geometric centre or axis, but this need not necessarily be the case. The present invention further provides a layered body obtainable by the process according to the fifth aspect.
- In a sixth aspect, the present invention provides a composition comprising a plurality of bodies of the first aspect and/or a plurality of bodies of the second aspect.
- The present inventors have found that the layered bodies of the first aspect have advantages over the prior art. They find use in many applications, such as drug delivery, catalysis and protecting sensitive agents. For example, it is considered that they can be used in ultrasound and can increase the non-linear effect of an ultrasound diagnostic. They can also have many layers, which could have differing properties, and, in some embodiments, a gas-containing core region and a gas-containing intermediate layer, which enables selective destruction of the layers, which may be used to release different active agents, e.g. therapeutic or diagnostic agents, at different times. The layered bodies of the second aspect have advantages over the prior art, especially multilayered bodies produced using layer-by-layer techniques. The layered bodies of the second aspect can be formed much quicker than those of the layer-by-layer techniques, for example in electrohydrodynamic processes, e.g. a process of the fourth or fifth aspect. The removal of the core region in layer-by-layer formed bodies also involves techniques that can be detrimental to the bodies and/or involve agents that could be harmful if the layered body is used as a pharmaceutical, whereas the layered bodies produced in accordance with the present invention can avoid such difficulties. The present inventors have also found that the processes described herein allow a greater control of the thickness of the various layers, and therefore the volume of material in the various layers, than at least some of the processes described in the prior art. This can be of importance when aiming to standardise the content of the layered bodies produced in accordance with the processes of the present invention, which has particular importance in the pharmaceutical use of the layered bodies, such that rate of degradation and release of any therapeutic or diagnostic agents can be more accurately predicted. The control of the thickness of layers is also advantageous in being able to more closely control the energy absorption characteristics of the layered bodies, which can be useful in ultrasound applications.
-
FIG. 1 shows an embodiment of the device of the present invention, the embodiment comprising a four-needle electrohydrodynamic system. -
FIGS. 2A and 2B shows the four-needle electrohydrodynamic system ofFIG. 1 in more detail, the use of which is described in the detailed description and Examples below. -
FIGS. 3A and 3B shows photographs of the needles used in the electrohydrodynamic system ofFIGS. 1 and 2 , withFIG. 3A showing the separate needles, andFIG. 3B showing the needles assembled. -
FIGS. 4A to 4D show schematic cross-sectional views of embodiments of the layered bodies of the present invention. -
FIG. 5 shows an embodiment of a composition comprising a plurality of layered bodies of the present invention, in particulate or capsule form, obtained as described in the Examples below. -
FIG. 6 shows an embodiment of a composition comprising a plurality of layered bodies of the present invention, in particulate or capsule form, obtained as described in the Examples below. -
FIG. 7 shows the cross section of either capsule or a thread and how the diameter of the capsule or thread can be measured, for example either at the widest point (horizontal diameter in this Figure) or at its narrowest point (vertical diameter in this Figure). -
FIG. 8 shows the layered body ofFIG. 4B , with the core region RC and surrounding intermediate layer RI1 having shifted due to gravity within the gas-containing layer RI2, such that it is in contact with the outer layer RO. -
FIG. 9 shows the layered body of 4C, with the with the core region RC and surrounding intermediate layer RI1 having shifted due to gravity within the gas-containing layer RI2, such that it is in contact with the outer layer RO. - In a first aspect, the present invention provides a layered body comprising:
- a core region;
- at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer,
- wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 μm or less. The core region may have a substantially circular cross section. The layered body of the first aspect may be producible from the process of fourth aspect. This has typically been found to produce a core region having a substantially circular cross section. In an embodiment, the at least one intermediate layer least partially surrounds, optionally completely surrounds, the core region. In an embodiment, the outer layer at least partially surrounds, optionally completely surrounds, the at least one intermediate layer. In an embodiment, the outer layer surrounds at least part of, optionally all of the, the core region. Typically, the at least one intermediate layer and the outer layer share the same core region. In an embodiment, the at least one intermediate layer and the outer layer are disposed concentrically around the core region. In an embodiment, “disposed concentrically”, indicates that the at least one intermediate layer surrounds the core region and the outer layer surrounds the at least one intermediate layer; “disposed concentrically” covers embodiments where the core region is circular in cross section and non-circular in cross section. In an embodiment, “disposed concentrically” indicates that the core region and the at least one intermediate layer share the same core, but they need not necessarily share the same geometric centre (for example when the body is in the form of a capsule) or axis (for example when in the body is in the form of a thread).
- In an embodiment in which there are two or more intermediate layers, preferably, the intermediate layer disposed closest to the core is surrounded at least partially, optionally completely, by the other intermediate layer or layers. In an embodiment in which there are two or more intermediate layers, the outer layer preferably at least partially, optionally completely, surrounds the intermediate layers.
- The core region may be any suitable shape. It may or may not have a circular cross section. It may or may not have an oval cross section. The core region may or may not be spherical or approximately spherical in shape. The core region may have a shape selected from spherical, substantially spherical, spheroid, ellipsoidal and substantially ellipsoid. The core region may be elongated in shape.
- In an embodiment, the layered body may be in the form of a capsule. The core region of the capsule may have a shape selected from spherical, substantially spherical, spheroid, ellipsoidal and substantially ellipsoid. The capsule may have core region that is encompassed, e.g. partially or entirely, by the least one intermediate layer, which, in turn, is or are (if there is more than one intermediate layer) encompassed by the outer layer. The capsule may have a substantially spherical core region, with the at least one intermediate layer and the outer layer in the form of approximate spheres arranged around, e.g. concentrically around, the core region. If the body is in the form of a capsule, the at least one dimension measured across the body may be the diameter across the capsule, optionally the largest diameter. The measurement may be made for example by obtaining an image of the capsule using a suitable means, such as scanning electron microscopy, and measuring the diameter across the capsule. This is illustrated on a schematic drawing of a layered body in
FIG. 7 . Optionally, the diameter of the body can be measured at its widest point (horizontal diameter inFIG. 7 ) or at its narrowest point (vertical diameter inFIG. 7 ). - In an embodiment, the layered body may be in an elongated form. The body may have an elongated core, with the at least one intermediate layer disposed around, e.g. radially around, the elongated core, and the outer layer disposed around, e.g. radially around, the at least one intermediate layer. The at least one intermediate layer may extend along at least part of, optionally the whole of, the length of the core region. The outer layer may extend along at least part of, optionally whole of, the length of the core region. When the body is elongate, it may have two opposing ends. The at least one intermediate layer may or may not cover one or both ends of the core region of elongate body. The outer layer may or may not cover one or both ends of elongate body. The body may have an elongated core having an axis, and the at least one intermediate layer and the outer layer being disposed around, e.g. radially around, the axis, with the intermediate layer being disposed between the outer layer and the core region. The body may have an elongated core region having an axis, and the at least one intermediate layer and the outer layer being disposed concentrically around, the axis. The elongated form may, for example, be in the form of an elongated particle or in the form of a thread. If the body is in elongated form having an axis the at least one dimension measured across the body may be a diameter of the elongated form, measured in a direction perpendicular to the axis. If the body is in the form of a thread, the at least one dimension measured across the body may be the diameter of the thread. The measurement may be made for example by obtaining an image of the thread using a suitable means, such as a scanning electron microscopy, and measuring the diameter of the thread.
- In an embodiment, the core region and the outer layer each independently comprises a solid or a liquid medium, and the at least one intermediate layer comprises a gas. In an embodiment, the body comprises at least two intermediate layers, the core region and the outer layer each independently comprises a solid or a liquid medium, at least one of the intermediate layers comprises a gas and at least one of the intermediate layers comprises a solid or liquid medium.
- In an embodiment, at least two intermediate layers are disposed around, optionally concentrically around, the core region. In an embodiment, the core comprises or consists of a gas. In an embodiment, an intermediate layer disposed adjacent the core region defines a hollow core region, and the hollow core region comprises or consists of a gas. In an embodiment, at least two intermediate layers are disposed around, optionally concentrically around, the core region, an intermediate layer disposed adjacent the core region defines a hollow core region, the hollow core region comprising a gas, and one or more of the other intermediate layers comprises a gas. The layered body may be formed according to the process of the fourth or fifth aspect and the gas in the at least one intermediate layer, and optionally in the core region (if it contains a gas), may comprise (i) a gas from the environment into which the fluid mediums pass into when exiting the channels and/or (ii) a gas formed from the vaporisation of the volatile liquid of the second fluid medium, which may be as described herein.
- In an embodiment, the core region comprises or consists of a first gas, at least two intermediate layers are disposed around, optionally concentrically around, the core region, the intermediate layer disposed adjacent the core region comprising a solid or a liquid medium, and at least one of the further outwardly disposed intermediate layers comprises a second gas. The first and second gas may be the same or different.
- In a second aspect, the present invention provides a layered body comprising:
- a core region having a substantially circular cross section;
- at least two intermediate layers disposed around the core region;
- an outer layer disposed around the at least two intermediate layers,
- the layered body having at least one dimension, measured across the body and through the core region, of 100 μm or less. In an embodiment, the layered body may be in the form of a capsule. In an embodiment, the layered body may be in the form of a thread. The layered body of the second aspect may be producible from the process of the fifth aspect. This has typically been found to produce a core region having a substantially circular cross section. In an embodiment, one of the intermediate layers least partially surrounds, optionally completely surrounds, the core region. Optionally, the intermediate layer disposed closest to the core is surrounded at least partially, optionally completely, by the other intermediate layer or layers. The outer layer preferably at least partially, optionally completely, surrounds the intermediate layers. In an embodiment, the outer layer surrounds at least part of, optionally all of the, the core region. In an embodiment, the at least two intermediate layers and the outer layer share the same core region. In an embodiment, the at least two intermediate layers and the outer layer are disposed concentrically around the core region. In an embodiment, “disposed concentrically”, indicates that the at least two intermediate layers surround the core region and the outer layer surrounds the at least two intermediate layers; “disposed concentrically” covers embodiments where the core region is circular in cross section and non-circular in cross section. In an embodiment, “disposed concentrically” indicates that the core region and the at least two intermediate layers share the same core, but they need not necessarily share the same geometric centre or axis.
- In an embodiment, the core region comprises or consists of a gas. In an embodiment, an intermediate layer disposed adjacent the core region defines a hollow core region, and the hollow core region comprises or consists of a gas.
- In an embodiment, at least one of the at least two intermediate layers comprises a gas.
- In an embodiment, the core region and at least one of the at least two intermediate layers comprise a gas.
- Preferably, the gas in the at least one intermediate layer and/or the core region comprises a gas selected from oxygen and nitrogen.
- At least one of the core region, the intermediate layer or layers and the outer layer may comprise one or more solid or liquid substances. At least one of the core region, the intermediate layer or layers and the outer layer may comprise one or more pharmaceutically acceptable substances. The one or more solid or liquid substances may be carrier substances, suitable for acting as carriers for one or more active agents, optionally agents selected from diagnostic and therapeutic agents. The one or more solid or liquid substances may be or comprise an organic substance, optionally a polymer. The one or more solid or liquid substances preferably comprise a biocompatible carrier substance. The one or more solid or liquid substances may be selected from poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polymethylsilsesquioxane (PMSQ), perfluorohexane (PFH), perfluoropentane (PFP), polyurethane, starch, albumin, polyethylene oxide (PEO), glycerol and oil, such as olive oil.
- Particularly preferred polymers include, but are not limited to sodium polystyrene sulfonate (PSS), polyethers, such as a polyethylene oxide (PEO), polyoxyethylene glycol or polyethylene glycol (PEG), polyethylene imine (PEI), a biodegradable polymer such as a polylactic acid, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) (PLGA), polymethylsilsesquioxane (PMSQ) and copolymers, derivatives, and mixtures thereof. Other polymers that may be used include those well known to those of skill in the art to be used in cell cultures, implants, regenerative, therapeutic, and pharmaceutical compositions. One such example is polyvinylpyrrolidone (PVP).
- Optionally, the polymer may have a property selected from: being positively-charged being (cationic), being negatively-charged (anionic), being polyethylene glycol(PEG)-ylated, being covered with a zwitterion, being hydrophobic, being superhydrophobic (for example having with water contact angles in excess of 150°), being hydrophilic, being superhydrophilic (for example, where the water contact angle is near or at 0°), being olephobic/lipophobic, being olephilic/lipophilic, and/or nanostructured, among others.
- The polymer may be a water-soluble and/or hydrophilic polymer, which may be selected from biocompatible polymers, including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and mixtures thereof.
- The polymer may also be selected from polyvinylpyrrolidone, vinyl acetate, polyvinylpyrrolidone-vinyl acetate copolymers, polyvinyl alcohol (PVA), acrylates and polyacrylic acid (PAA), including polyacrylate polymer, vinylcaprolactam/sodium acrylate polymers, methacrylates, poly(acryl amide-co-acrylic acid) (PAAm-co-AA), vinyl acetate and crotonic acid copolymers, polyacrylamide, polyethylene phosphonate, polybutene phosphonate, polystyrene, polyvinylphosphonates, polyalkylenes, and carboxy vinyl polymer. The multiphasic fiber compositions may comprise derivatives, copolymers, and further combinations of such polymers, as well.
- The polymer may be selected from water insoluble or hydrophobic polymers including, but not limited to, cellulose acetate, cellulose nitrate, ethylene-vinyl acetate copolymers, vinyl acetate homopolymer, ethyl cellulose, butyl cellulose, isopropyl cellulose, shellac, hydrophobic silicone polymer (e.g., dimethylsilicone), polymethyl methacrylate (PMMA), cellulose acetate phthalate and natural or synthetic rubber; siloxanes, such as polydimethylsiloxane (PMDS), cellulose, polyethylene, polypropylene, polyesters, polyurethane and nylon, including copolymers, derivatives, and combinations thereof.
- The polymers may be crosslinked, optionally after formation of the body, for example by the application of heat, ionizing radiation or other methods of curing and treating polymers known to those of skill in the art.
- Optionally, the polymer may be selected from sodium alginate, carrageenan, xanthan gum, gum acacia, Arabic gum, guar gum, pullulan, agar, chitin, chitosan, pectin, karaya gum, locust bean gum, various polysaccharides; starches such as maltodextrin, amylose, corn starch, potato starch, rice starch, tapioca starch, pea starch, sweet potato starch, barley starch, wheat starch, modified starch (e.g., hydroxypropylated high amylose starch), dextrin, levan, elsinan and gluten; and proteins such as collagen, whey protein isolate, casein, milk protein, soy protein, keratin, and gelatin.
- The layered body may comprise an active agent, for example in one or more of the core region, the intermediate layer or layers or the outer layer. The active agent in the body may be selected from pharmaceutical and/or cosmetic active agents, which may be selected from growth factors; growth factor receptors; transcriptional activators; translational promoters; antiproliferative agents; growth hormones; anti-rejection drugs; anti-thrombotic agents; anti-coagulants; stem cell or gene therapies; antioxidants; free radical scavengers; nutrients; co-enzymes; ligands; cell adhesion peptides; peptides; proteins; nucleic acids; DNA; RNA; sugars; saccharides; nutrients; hormones; antibodies; immunomodulating agents; growth factor inhibitors; growth factor receptor antagonists; transcriptional repressors; translational repressors; replication inhibitors; inhibitory antibodies; cytotoxin; hormonal agonists; hormonal antagonists; inhibitors of hormone biosynthesis and processing; antigestagens; antiandrogens; anti-inflammatory agents; non-steroidal antiinflammatory agents (NSAIDs); analgesics; COX-I and II inhibitors; antimicrobial agents; antiviral agents; antifungal agents; antibiotics; anti-proliferative agents; antineoplastic/antiproliferative/anti-miotic agents; anesthetic, analgesic or pain-killing agents; antipyretic agents, prostaglandin inhibitors; platelet inhibitors; DNA de-methylating agents; cholesterol-lowering agents; vasodilating agents; endogenous vasoactive interference agents; angiogenic substances; cardiac failure active ingredients; polysaccharides; sugars; targeting toxin agents; aptamers; quantum dots; nano-materials; nano-crystals; and combinations thereof.
- The layered body may comprise a diagnostic agent, for example in one or more of the core region, the intermediate layer or layers or the outer layer. The diagnostic agent in the body may be an agent suitable for use in a technique selected from, but not limited to, diagnostic medical imaging procedures (for example, radiographic imaging (x-ray), fluorescence spectroscopy, Forster/fluorescent resonance energy-transfer (FRET), computed tomography (CT scan), magnetic resonance imaging (MRI), positron emission tomography (PET), other nuclear imaging, and the like. The diagnostic agent may be an agent for use in diagnostic imaging, for example a contrast agents, such as barium sulfate for use with MRI, for example, or fluorescein isothiocyanate (FITC).
- At least one of the core region, the intermediate layer or layers, and the outer layer may comprise an active agent selected from a diagnostic agent and a therapeutic agent. The diagnostic agent may be selected from, for example, contrast agents, e.g. contrast agents for use in MRI techniques, and luminescent agents, e.g. fluorescent agents. The therapeutic agent may be a drug for the treatment or prevention of a disease. Optionally at least one or the core region, the intermediate layer or layers, and the outer layer may comprises an agent selected from a peptide, DNA and RNA.
- Suitable active agents for use in such pharmaceutically and/or cosmetically acceptable compositions are well known to those of skill in the art and include, by way of non-limiting example, those disclosed in the Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Thirteenth Edition (2001) by Merck Research Laboratories and the International Cosmetic Ingredient Dictionary and Handbook, Tenth Ed., 2004 by Cosmetic Toiletry and Fragrance Association, and U.S. Pat. Nos. 6,589,562, 6,825,161, 6,063,365, and 6,491,902, all to Shefer et al, each incorporated herein by reference.
- Optionally, at least one of the core region, the intermediate layer or layers, and the outer layer may comprise a diagnostic agent and another of the core region, the intermediate layer or layers, and the outer layer comprises a therapeutic agent.
- The at least one dimension, measured across the body and through the core region, is 100 μm or less, optionally 50 μm or less, optionally 30 μm or less, optionally 20 μm or less, optionally 10 μm or less, optionally 1 μm or less, optionally 500 nm or less, optionally 200 nm or less. It the body is in the form of a capsule, the dimension may be the diameter of the capsule, optionally the diameter of the capsule at its widest point. It the body is in the form of a thread, the dimension may be the diameter of the thread, optionally the diameter of the thread at its widest point. The measurement of the dimension may be made for example by obtaining an image of the body using a suitable means, such as scanning electron microscopy, and measuring the dimension across the body.
- In a third aspect, the present invention provides an electrohydrodynamic device for producing one or more layered bodies,
- the device comprising
- at least four concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least two intermediate concentrically disposed tubular channels, and an outer concentrically disposed tubular channel; and
- a means for applying a voltage to the needles.
- The needles are able to be charged by applying a voltage to the needles. The needles are preferably made from an electrically conducting material, preferably a metal. The metal may be selected from, for example, an elemental metal or a metal alloy. The metal may, for example, comprise steel.
- The innermost needle in the device, which defines the hollow core, may have an inner diameter of at least 0.01 mm, preferably at least 0.1 mm. The innermost needle in the device, which defines the hollow core, may have an inner diameter of from 0.01 mm to 2 mm, optionally from 0.05 to 1.5 mm, optionally from 0.15 to 1.0 mm, optionally from 0.15 to 0.25 mm, optionally about 0.2 mm
- The space between the outer surface of a needle and the inner surface of the outwardly disposed adjacent needle may be from 0.01 mm to 1.5 mm, preferably 0.1 mm to 1 mm, optionally 0.2 to 0.9 mm, optionally 0.3 to 0.7 mm, optionally about 0.5 mm Optionally the space between the outer surface of each needle (except the outer needle) and the inner surface of the outwardly disposed adjacent needle may be from 0.01 mm to 1.5 mm, preferably 0.1 mm to 1 mm, optionally 0.2 to 0.9 mm, optionally 0.3 to 0.7 mm, optionally about 0.5 mm
- In an embodiment, the device comprises an inner needle, which defines the hollow core, which has an inner diameter of from 0.15 to 1.0 mm, optionally from 0.15 to 0.25 mm, optionally about 0.2 mm, at least three needles disposed outwardly in a concentric manner from the innermost needle, wherein the space between the outer surface of each needle (except the outer needle) and the inner surface of the outwardly disposed adjacent needle is from 0.01 mm to 1.5 mm, preferably 0.1 mm to 1 mm, optionally 0.2 to 0.9 mm, optionally 0.3 to 0.7 mm, optionally about 0.5 mm
- The means for applying a voltage to the needles may apply any suitable voltage. The voltage may be from 1 kV to 50 kV, preferably 3 kV to 30 kV, more preferably 15 kV to 25 kV, optionally about 20 kV. The means for supplying a voltage may apply a dc voltage or an ac voltage. A ground electrode may be present, which may be at or near the collection means. Optionally the ground electrode is a ring electrode, which may be placed such that the centre of the ring is along the axis formed by the innermost needle. The ground electrode may be placed at any suitable distance from the needles, for example a distance of from 1 mm to 1 m, optionally 1 mm to 50 cm, optionally 1 mm to 10 cm, optionally 1 mm to 20 mm, optionally 5 mm to 15 mm, optionally about 12 mm
- The device optionally further comprises means for supplying a fluid to each channel. The means for supplying a fluid to each channel preferably can supply a fluid medium selected from the first and second fluid medium. Preferably, at least one of the intermediate concentrically disposed channels is in fluid connection with a means for supplying the first fluid medium; and optionally the remaining channels are in fluid connection with a fluid medium selected from the first fluid medium and the second fluid medium. The means for supplying a fluid to each channel preferably comprises a syringe pump. Preferably a syringe pump is in fluid connection with one end of each channel. Each means for supplying a fluid can preferably supply a fluid medium at a rate of from 1 μl/min to 2000 μl/min, optionally from 50 to 1000 μl/min, optionally from 100 to 800 μl/min.
- Optionally, the device further comprises a collection means for collecting the fluid mediums exiting the needles and/or the layered body or bodies formed therefrom. The collection means is preferably earthed. The collection means may be a receptacle.
- The device may further comprise a means for observing the fluid mediums exiting the needles and/or the layered body or bodies formed therefrom. The means for observing may comprise a camera, optionally connected to a recording means. The camera may optionally be connected to a visual display means, so that the fluid mediums exiting the needles and/or the layered body or bodies formed therefrom exiting the needles can be observed.
- In a fourth aspect, the present invention provides a process for producing one or more layered bodies, the process
- comprising:
- providing an electrohydrodynamic device, the device comprising at least three concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least one intermediate concentrically disposed tubular channel, and an outer concentrically disposed tubular channel,
- a means for applying a voltage to the needles,
- providing a first fluid medium comprising a liquid comprising a non-volatile component
- providing a second fluid medium comprising or consisting of a volatile liquid,
- passing the second fluid medium through an intermediate concentrically disposed tubular channel, and, at the same time,
- passing the first fluid medium through each of the plurality of channels disposed adjacent to the intermediate concentrically disposed tubular channel through which the second fluid medium is passed,
- and applying a voltage to the needles,
- such that, on leaving the needles, one or more layered bodies is or are formed. This method involves passing the first fluid medium through each of the plurality of channels disposed adjacent to the intermediate concentrically disposed tubular channel through which the second fluid medium is passed. If the device comprises three concentrically arranged, spaced apart hollow needles, it has a core channel, a single intermediate concentrically disposed tubular channel, and an outer channel, with the core channel and the outer channel being disposed adjacent to the intermediate concentrically disposed tubular channel. Accordingly, if the device comprises three concentrically arranged, spaced apart hollow needles, the second fluid medium is passed through the intermediate concentrically disposed tubular channel, and the first fluid medium is passed through the core channel and the outer concentrically disposed tubular channel.
- In an embodiment, the device of this aspect comprises at least four concentrically arranged, spaced apart hollow needles, the needles together defining a core channel, at least two intermediate concentrically disposed tubular channel, and an outer concentrically disposed tubular channel, and the fluid medium passed through at least one of the at least two intermediate concentrically disposed tubular channels is the second fluid medium, and optionally the fluid medium passed through the core channel is the second fluid medium.
- In a fifth aspect, the present invention provides a process for producing one or more layered bodies, the process comprising:
- providing the electrohydrodynamic device according to the third aspect,
- passing fluid mediums through the hollow core, the at least two intermediate concentrically disposed tubular channels, and the outer concentrically disposed tubular channel,
- and applying a voltage to the needles, such that, on leaving the needles, one or more layered bodies is or are formed. The fluid mediums may be selected from a first fluid medium comprising a liquid comprising a non-volatile component and a second fluid medium comprising or consisting of a volatile liquid.
- The processes of the fourth or fifth aspect may be electrohydrodynamic processes. As the fluid mediums leave the needles, typically a jet of the fluid mediums is formed, which then either breaks up into capsules or remains intact to produce a thread.
- The first fluid medium comprises a liquid comprising a non-volatile component. The liquid of the first fluid medium may be the non-volatile component. The liquid may have a boiling point of at least 100° C., optionally at least 150° C., optionally at least 200° C., optionally at least 250° C. All boiling and melting points given herein, unless otherwise stated, are measured at standard pressure (101.325 kPa). The liquid may comprise an organic solvent. The organic solvent may comprise a non-polar solvent and/or a polar solvent. The organic solvent may comprise an aprotic solvent and/or a protic solvent. Non-polar solvents include, but are not limited to, pentane, cyclopentane, hexane, benzene, toluene, 1,4-dioxane, chloroform, and diethylether. The solvent may comprise a polar aprotic solvent, optionally selected from dichloromethane, tetrahydrofuran, ethylacetate, acetone, dimethylformamide, acetonitrile, dimethyl sulphoxide. The solvent may comprise a polar protic solvent, optionally selected from formic acid, n-butanol, isopropanol, n-propanol, ethanol, methanol and acetic acid. The organic solvent may comprise a hydrocarbon. The hydrocarbon may comprise an aromatic or an aliphatic hydrocarbon. The hydrocarbons may be selected from, but are not limited to, pentane, cyclopentane, hexane, cyclohexane and benzene.
- The first fluid medium preferably has a dynamic viscosity of 1.5 mPas or more, optionally a dynamic viscosity of 1.6 mPas or more, optionally a dynamic viscosity of 1.7 mPas or more. The dynamic viscosity is measured at standard temperature (25° C.) and pressure (101.325 kPa). The dynamic viscosity of the first fluid medium is preferably more than the dynamic viscosity of the second fluid medium, when measured under the same conditions. Dynamic viscosity values can be measured according to a standard method known to those skilled in the art, for example by using a U-tube viscometer or a rotational viscometer, such as a commercially available VISCOEASY rotational viscometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- The first fluid medium preferably has a surface tension of 20 mNm−1 or more, optionally 25 mNm−1 or more, optionally 30 mNm−1 or more. The first fluid medium preferably has a surface tension of 20 mNm−1 to 30 mNm−1. The surface tension of the first fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa). The surface tension of the first fluid medium is preferably more than the surface tension of the second fluid medium, when measured under the same conditions. Surface tension can be measured according to a standard method known to those skilled in the art, for example by using a tensiometer, e.g. a commercially available Kruss Tensiometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- The conductivity of the first fluid medium is preferably 1×10−8 Sm−1 or more, optionally 1×10−7 Sm−1 more, optionally 1×10−6 Sm−1 or more, optionally 1×10−5 Sm−1 or more. Conductivity in this context refers to the electrical conductivity. The conductivity of the first fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa). The conductivity of the first fluid medium is preferably more than the conductivity of the second fluid medium, when measured under the same conditions. Conductivity can be measured according to a standard method known to those skilled in the art, for example by using a conductivity probe, such as the commercially available HI-8733 conductivity probe, available from Sigma-Aldrich. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- The liquid of the first fluid medium may be any suitable liquid in which a non-volatile component, e.g. a polymer, can be dissolved and/or suspended. The non-volatile component, e.g. a polymer, may be completely dissolved in the liquid of the first fluid medium. The non-volatile component may be an organic substance, optionally a polymer. The non-volatile component preferably has a melting point of at least 100° C., optionally at least 150° C., optionally at least 200° C., optionally at least 250° C. The non-volatile component preferably comprises a polymer. The non-volatile component, e.g. a polymer, may be present in the liquid of the first fluid medium in an amount of at least 1% by weight, preferably at least 10% by weight, optionally at least 20% by weight, optionally at least 40% by weight, optionally at least 50% by weight, optionally at least 60% by weight, optionally at least 70% by weight, optionally at least 80% by weight. It has been found that if at least one of the fluid mediums comprises at least 60% by weight of a polymer, particularly the fluid medium passed down the outer concentrically disposed channel, the formation of a layered body in the form of a thread is promoted. Likewise, it has been found if at least one of the fluid mediums comprises less than 60% by weight of a polymer, particularly the fluid medium passed down the outer concentrically disposed channel, the formation of layered bodies in the form of capsules is promoted. Accordingly, in an embodiment, at least one of the fluid mediums, optionally the fluid medium passed down the outer concentrically disposed channel, comprises a polymer in an amount of 60% by weight or more. Accordingly, in an embodiment, at least one of the fluid mediums, optionally the fluid medium passed down the outer concentrically disposed channel, comprises a polymer in an amount of less than 60% by weight.
- Particularly preferred polymers for use in the first fluid medium include, but are not limited to sodium polystyrene sulfonate (PSS), polyethers, such as a polyethylene oxide (PEO), polyoxyethylene glycol or polyethylene glycol (PEG), polyethylene imine (PEI), a biodegradable polymer such as a polylactic acid, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) (PLGA), polymethylsilsesquioxane (PMSQ) and copolymers, derivatives, and mixtures thereof. Other polymers that may be used include those well known to those of skill in the art to be used in cell cultures, implants, regenerative, therapeutic, and pharmaceutical compositions. One such example is polyvinylpyrrolidone (PVP).
- Optionally, the polymer for use in the first fluid medium may have a property selected from: being positively-charged being (cationic), being negatively-charged (anionic), being polyethylene glycol(PEG)-ylated, being covered with a zwitterion, being hydrophobic, being superhydrophobic (for example having with water contact angles in excess of 150°), being hydrophilic, being superhydrophilic (for example, where the water contact angle is near or at 0°), being olephobic/lipophobic, being olephilic/lipophilic, and/or nanostructured, among others.
- The polymer for use in the first fluid medium may be a water-soluble and/or hydrophilic polymers, which may be selected from biocompatible polymers, including, but not limited to, cellulose ether polymers, including those selected from the group consisting of hydroxyl alkyl cellulose, including hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), methyl cellulose (MC), carboxymethyl cellulose (CMC), and mixtures thereof.
- The polymer for use in the first fluid medium may also be selected from polyvinylpyrrolidone, vinyl acetate, polyvinylpyrrolidone-vinyl acetate copolymers, polyvinyl alcohol (PVA), acrylates and polyacrylic acid (PAA), including polyacrylate polymer, vinylcaprolactam/sodium acrylate polymers, methacrylates, poly(acryl amide-co-acrylic acid) (PAAm-co-AA), vinyl acetate and crotonic acid copolymers, polyacrylamide, polyethylene phosphonate, polybutene phosphonate, polystyrene, polyvinylphosphonates, polyalkylenes, and carboxy vinyl polymer. The multiphasic fiber compositions may comprise derivatives, copolymers, and further combinations of such polymers, as well.
- The polymer for use in the first fluid medium may be selected from water insoluble or hydrophobic polymers including, but not limited to, cellulose acetate, cellulose nitrate, ethylene-vinyl acetate copolymers, vinyl acetate homopolymer, ethyl cellulose, butyl cellulose, isopropyl cellulose, shellac, hydrophobic silicone polymer (e.g., dimethylsilicone), polymethyl methacrylate (PMMA), cellulose acetate phthalate and natural or synthetic rubber; siloxanes, such as polydimethylsiloxane (PMDS), cellulose, polyethylene, polypropylene, polyesters, polyurethane and nylon, including copolymers, derivatives, and combinations thereof.
- The polymers for use in the first fluid medium may be crosslinked, optionally after formation of the body, for example by the application of heat, ionizing radiation or other methods of curing and treating polymers known to those of skill in the art.
- Optionally, the polymer for use in the first fluid medium may be selected from sodium alginate, carrageenan, xanthan gum, gum acacia, Arabic gum, guar gum, pullulan, agar, chitin, chitosan, pectin, karaya gum, locust bean gum, various polysaccharides; starches such as maltodextrin, amylose, corn starch, potato starch, rice starch, tapioca starch, pea starch, sweet potato starch, barley starch, wheat starch, modified starch (e.g., hydroxypropylated high amylose starch), dextrin, levan, elsinan and gluten; and proteins such as collagen, whey protein isolate, casein, milk protein, soy protein, keratin, and gelatin.
- If a first fluid medium, as described herein, is passed through two adjacent channels, preferably, the first fluid mediums in one of these channels is immiscible with the first fluid medium in the adjacent channel. The first fluid mediums should be sufficiently immiscible such that two distinct phases form in the layered bodies. A person skilled in the art of electrohydrodynamic techniques could select appropriate first fluid mediums.
- The second fluid medium comprises or consists of a volatile liquid. In an embodiment, the volatile liquid is a liquid that has a boiling point not higher than 50° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels, optionally not higher than 40° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels, optionally not higher than 35° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels, optionally not higher than 30° C. above the temperature of the environment into which the fluid mediums pass into when exiting the channels. For example, if the temperature of the environment into which the fluid mediums pass into when exiting the channels is 25° C., preferably, the volatile liquid has a boiling point of 75° C. or less. The volatile liquid may have a boiling point of less than 100° C., optionally less than 80° C., optionally less than 70° C., optionally less than 60° C., optionally less than 50° C.
- The temperature of the environment into which the fluid mediums pass into when exiting the channels may be any suitable temperature. The process may be carried out such that the temperature of the environment into which the fluid mediums pass into when exiting the channels is at or above the boiling point of the liquid of the second fluid medium. The temperature of the environment into which the fluid mediums pass into when exiting the channels may be above 15° C., optionally above 20° C., optionally above 25° C. The temperature of the environment into which the fluid mediums pass into when exiting the channels may be less than 150° C., optionally less than 100° C., optionally less than 80° C., optionally less than 60° C., optionally less than 40° C. The temperature of the environment into which the fluid mediums pass into when exiting the channels may be from 10 to 40° C., optionally from 20 to 30° C. It has been surprisingly found that when a second fluid medium as described herein is passed down the intermediate channel (with the first fluid medium being passed down the other channels as described herein), a layered body is formed that has a intermediate layer comprising a gas.
- The environment into which the fluid mediums pass into when exiting the channels may or may not contain a gas. Preferably, the environment into which the fluid mediums pass into when exiting the channels contains a gas, which may comprise a gas selected from nitrogen, oxygen, and a gas from Group 18 of the periodic table. The gas from Group 18 of the periodic table may be selected from helium, neon and argon. The environment into which the fluid mediums pass into when exiting the channels may contain air.
- The environment into which the fluid mediums pass into when exiting the channels may contain a gas and be at a pressure of from 80 kPa to 120 kPa, optionally 90 to 110 kPa, optionally 95 to 105 kPa, optionally around standard pressure (101.325 kPa).
- The volatile liquid may be selected from a non-polar liquid, a polar aprotic liquid, and polar protic solvents. Preferably, the volatile liquid comprises or is a perhalocarbon, most preferably a perfluorocarbon. Perhalocarbons are organic compounds consisting of carbon and halogen atoms. Perfluorocarbons are organic compounds consisting of carbon and fluorine atoms. Preferably the perhalocarbon, e.g. the perfluorocarbon, contains 10 carbon atoms or less, optionally 9 carbons atoms or less, optionally 8 carbons atoms or less, optionally 7 carbons or less, optionally 6 carbons or less, optionally 5 carbons or less, optionally 4 carbons or less. Preferably the perhalocarbon, e.g. the perfluorocarbon, contains 3 or more carbon atoms, optionally 4 or more carbon atoms. The perfluorocarbon may be selected from, but is not limited to, octafluoropropane, perfluorohexane, perfluoropentane, and perfluorodecalin.
- The volatile liquid may comprise a halogenated hydrocarbon, which may be selected from, but is not limited to, a halogenated alkane, halogenated alkene and halogenated alkyne. The hydrocarbon may be branched or linear, and optionally substituted with one or more substituents other than a halogen. The halogenated hydrocarbon may have one or more halogens on each molecule, which may be selected from fluorine, chlorine, bromine and iodine. The halogenated hydrocarbon is preferably a fluoroalkyl. The halogenated hydrocarbon may contain 10 carbons or less, optionally 9 carbons atoms or less, optionally 8 carbons atoms or less, optionally 7 carbons or less, optionally 6 carbons or less, optionally 5 carbons or less, optionally 4 carbons or less. The halogenated hydrocarbon may contain 3 or more carbon atoms, optionally 4 or more carbon atoms.
- Optionally, the volatile liquid comprises a heterofluoroalkyl. Examples of heterofluoroalkyls include, but are not limited to, methoxynonafluorobutane and ethoxynonofluorobutane.
- The volatile solvent may comprise an organic solvent selected from, but not limited to, ethanol, acetone, ethyl acetate, acetates, alcohol, ether, aliphatic, aromatic hydrocarbons, chlorinated hydrocarbons, ketones and chloroform.
- The second fluid medium preferably has a dynamic viscosity of 1.3 mPas or less, optionally a dynamic viscosity of 1.2 mPas or less, optionally a dynamic viscosity of 1.1 mPas or less. The dynamic viscosity is measured at standard temperature (25° C.) and pressure (101.325 kPa). Dynamic viscosity values can be measured according to a standard method known to those skilled in the art, for example by using a U-tube viscometer or a rotational viscometer, such as a commercially available VISCOEASY rotational viscometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- The second fluid medium preferably has a surface tension of 20 mNm−1 or less, optionally 18 mNm−1 or less, optionally 15 mNm−1 or less, optionally 12 mNm−1 or less. The surface tension of the second fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa). Surface tension can be measured according to a standard method known to those skilled in the art, for example by using a tensiometer, e.g. a commercially available Kruss Tensiometer. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- The conductivity of the second fluid medium is preferably 1×10−8 Sm−1 or less, optionally 1×10−9 Sm−1 or less, optionally 1×10−10 Sm−1 or less, optionally 1×10−11 Sm−1 or less. The conductivity of the second fluid medium is measured at standard temperature (25° C.) and pressure (101.325 kPa). Conductivity can be measured according to a standard method known to those skilled in the art, for example by using a conductivity probe, such as the commercially available HI-8733 conductivity probe, available from Sigma-Aldrich. Ethanol may used as a calibrating medium in the relevant measurement equipment, if necessary.
- Preferably, the first and second fluid mediums are immiscible. Optionally the volatile liquid has a solubility in the liquid of the first fluid medium of 100 ppm or less, optionally 50 ppm or less, optionally 20 ppm or less, measured at standard temperature (25° C.) and pressure (101.325 kPa). In an embodiment, the first fluid medium comprises a non-halogenated organic solvent and the second fluid medium comprises a perhalocarbon and/or a halogenated hydrocarbon. In an embodiment, the first fluid medium comprises a non-halogenated organic solvent and the second fluid medium comprises a perfluorocarbon and/or a halogenated hydrocarbon having one or more fluorines on each molecule. The non-halogenated organic solvent may be selected from, but is not limited to, an aprotic solvent and a protic solvent. The non-halogenated organic solvent may be selected from ethanol, acetone, ethyl acetate, acetates, alcohol, ether, aliphatic, aromatic hydrocarbons, chlorinated hydrocarbons, ketones and chloroform. In an embodiment, the first fluid medium comprises a non-halogenated organic solvent and a polymer, and optionally the second fluid medium comprises a perfluorocarbon and/or a halogenated hydrocarbon.
- One or more of the fluid mediums passed down the channels may comprise one or more pharmaceutically acceptable substances. Optionally all of the fluid mediums passed down the channels are pharmaceutically acceptable substances. The pharmaceutically acceptable substances may be carrier substances, suitable for acting as carriers for one or more agents selected from diagnostic and therapeutic agents. The carrier species may be an organic substance, optionally a polymeric substance. The carrier species is preferably a biocompatible carrier species. The carrier species may be selected from poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polymethylsilsesquioxane (PMSQ), perfluorohexane (PFH), perfluoropentane (PFP), polyurethane, starch, albumin, polyethylene oxide (PEO), glycerol and oil, such as olive oil.
- The one or more fluid mediums, preferably the first fluid medium, may comprise a liquid having a pharmaceutically acceptable substance, e.g. the carrier substance, therapeutic agent and/or diagnostic agent as described herein, dispersed therein, e.g. dissolved therein or suspended therein. The liquid may comprise a polar or non-polar solvent. The liquid may comprise a protic or non-protic solvent. The liquid in the fluid medium may, for example, be as described above.
- The rate of passing the fluid mediums through the device may be any suitable rate. The rates may be varied according to the nature of the fluid medium, and the desired type of layered bodies to be formed. The rate of passing the fluid mediums through the device may be, for each fluid medium being passed through each channel, from 1 μl/min to 2000 μl/min, optionally from 50 to 1000 μl/min, optionally from 100 to 800 μl/min.
-
FIGS. 1, 2 and 3 shows an embodiment of the electrohydrodynamic device of the present invention. The device comprises four concentrically arranged, spaced apart hollow needles A, B, C and D, the needles together defining a core channel W, two intermediate concentrically disposed tubular channels X and Y, and an outer concentrically disposed tubular channel Z; and a means for applying a voltage to the needles. - As shown in
FIG. 1 , a syringe pump is fluidly connected to one end of each channel. The inner surface of the innermost needle A defines the core channel W. The core channel W is fluidly connected tosyringe 1, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone. - The outwardly disposed adjacent needle to the core needle is intermediate needle B. An intermediate concentrically disposed tubular channel X is defined by the outer surface of innermost needle A and inner surface of needle B. Tubular channel X is fluidly connected to
syringe 2, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone. - The outwardly disposed adjacent needle to intermediate needle B is intermediate needle C. An intermediate concentrically disposed tubular channel Y is defined by the outer surface of needle B and inner surface of needle C. Tubular channel Y is fluidly connected to
syringe 3, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone. - The outwardly disposed adjacent needle to intermediate needle C is outermost needle D. An outer concentrically disposed tubular channel Z is defined by the outer surface of innermost needle C and inner surface of needle D. Tubular channel Z is fluidly connected to
syringe 4, which may be via any suitable conduit such as a tube, preferably a tube comprising silicone. - As shown in
FIGS. 1, 2 and 3 , all needles have a free end through which the fluid mediums being passed through the needles can exit. The fluid mediums exiting the needles will together be termed a fluid composition from hereon. At the end of the needles distal to the free end, each of needles A, B and C is in flush connection with the adjacent outwardly disposed needle. -
FIG. 2B shows a cross-sectional view of the needles and the channels they define along the line A-A ofFIG. 2A .FIG. 2B shows the dimensions of a particular embodiment of the needles, as used in the Examples below. These dimensions can be varied and may be otherwise as described herein, depending on the desired size of the particles or threads that the skilled person wishes to produce with the device. InFIG. 2B , ID and OD represent, respectively, inner diameter and outer diameter. - In use, the needles may be orientated so that the axis of the needles is substantially vertical.
- As shown in
FIG. 1 , a collection means is provided for collecting the layered body or bodies formed from the fluid composition after exiting the needles. The collection means is earthed. The collection means is disposed below the needles. The collection means may be in any suitable form, for example a plate or a receptacle. -
FIGS. 3A and 3B show photographs of the needles used in the electrohydrodynamic system ofFIGS. 1 and 2 , withFIG. 3A showing the separate needles, andFIG. 3B showing the needles assembled. InFIG. 3A , the left hand needle is needle A, with needles B, C and D shown in order to the right. - In use,
syringe 1 can provide a liquid 1 to channel W, preferably a second fluid medium as described herein. In use,syringe 2 can provide a liquid 2 to channel X, preferably a first fluid medium as described herein. In use,syringe 3 can provide a liquid 3 to channel Y, preferably a second fluid medium as described herein. In use,syringe 4 can provide a liquid 4 to channel Z, preferably a first fluid medium as described herein. Each of the syringes preferably supplies a fluid medium, e.g. the first or second fluid medium as described herein, at a suitable rate, e.g. a rate of from 1 μl/min to 2000 μl/min, to the channel to which it is fluidly connected. The rate of supply of the fluid medium for each channel may be the same as or different to one or more of the other channels, e.g. the adjacent channel disposed outwardly or inwardly. -
FIGS. 4A to 4D show embodiments of the layered bodies of the present invention. InFIGS. 4A to 4C , the layered bodies are in the form of a capsule. InFIG. 4C , the layered body is in the form of a thread. - The layered body in
FIG. 4A is in the form of a capsule and comprises: a core region RC; two intermediate layers, RI1 and RI2, disposed around, e.g. concentrically around, the core region; an outer layer RO disposed around, e.g. concentrically around, the two intermediate layers. The diameter of the capsule is typically 100 μm or less. In the embodiment shown inFIG. 4A , the core region is substantially spherical. The intermediate layers and the outer layer are in the form of approximate spheres. In the embodiment shown inFIG. 4A , the core region RC is in the form an approximately spherical particle having a coating of intermediate layer RI1 surrounding the particle. The core region, the intermediate layers RI1 and RI2, and the outer layer RO all comprise liquid or solid materials. This is an embodiment of the second aspect of the invention. The body shown inFIG. 4A may be produced using the device shown inFIGS. 1 to 3B . In the process, the first fluid medium is passed down each of the four channels and an appropriate voltage applied to the needles, such that, when the fluid mediums exit the needles, they form a jet that breaks up into droplets, the droplets being in the form of the capsule shown inFIG. 4A . The droplets are collected on or in the earthed collecting means. - The layered body in
FIG. 4B is in the form of a capsule and comprises: a core region RC; two intermediate layers, RI1 and RI2 disposed around, e.g. concentrically around, the core region; an outer layer RO disposed around, e.g. concentrically around, the two intermediate layers. The diameter of the capsule is typically 100 μm or less. In the embodiment shown inFIG. 4B , the core region is substantially spherical. The intermediate layers and the outer layer are in the form of approximate spheres. In the embodiment shown inFIG. 4B , the core region RC is in the form an approximately spherical particle having a coating of intermediate layer RI1 surrounding the particle. The core region, the intermediate layers RI1, and the outer layer RO all comprise liquid or solid materials. The intermediate layer RI2 is a substantially hollow region comprising a gas, for example air. This is an embodiment of the first and second aspects of the invention. The body shown inFIG. 4B may be produced using the device shown inFIGS. 1 to 3B . In the process, the first fluid medium as described herein is passed down each of the channels W, X and Z, a second fluid medium as described herein, is passed down channel Y and an appropriate voltage applied to the needles, such that, when the fluid mediums exit the needles, they form a jet that breaks up into droplets, the droplets being in the form of the capsule shown inFIG. 4B . The droplets are collected on or in the earthed collecting means. The core and intermediate layers may alter positions to a small extent, such that the core region RC and surrounding intermediate layer RI1 shift, e.g. due to gravity, within the gas-containing layer RI2, such that the layer intermediate layer RI1 is in contact with the outer layer RO. This is shown inFIG. 8 . The layered body ofFIG. 8 is nevertheless encompassed by the first and second aspects of the invention. - The layered body in
FIG. 4C is in the form of a capsule and comprises: a core region RC; two intermediate layers, RI1 and RI2 disposed around, e.g. concentrically around, the core region; an outer layer RO disposed around, e.g. concentrically around, the two intermediate layers. The diameter of the capsule is typically 100 μm or less. In the embodiment shown inFIG. 4C , the core region is substantially spherical. The intermediate layers and the outer layer are in the form of approximate spheres. The intermediate layer RI1, and the outer layer RO all comprise liquid or solid materials. The core region RO and the intermediate layer RI2 are substantially hollow regions comprising a gas, for example air. This is an embodiment of the first and second aspects of the invention. The body shown inFIG. 4C may be produced using the device shown inFIGS. 1 to 3B . In the process, the first fluid medium as described herein is passed down each of the channels X and Z, the second fluid medium as described herein is passed down channels W and Y and an appropriate voltage applied to the needles, such that, when the fluid mediums exit the needles, they form a jet that breaks up into droplets, the droplets being in the form of the capsule shown inFIG. 4C . The droplets are collected on or in the earthed collecting means. The core and intermediate layers may alter positions to a small extent, such that the core region RC and surrounding intermediate layer RI1 shift, e.g. due to gravity, within the gas-containing layer RI2, such that the layer intermediate layer RI1 is in contact with the outer layer RO. This is shown inFIG. 9 . The layered body ofFIG. 9 is nevertheless encompassed by the first and second aspects of the invention. - The layered body in
FIG. 4D is in the form of a thread and comprises: a core region; two intermediate layers, disposed around, e.g. concentrically around, the core region; an outer layer disposed around, e.g. concentrically around, the two intermediate layers. The core is elongated and has an axis, and the two intermediate layers and the outer layer are disposed around, e.g. concentrically around, the axis. As can be seen inFIG. 4D , the core forms a substantially cylindrical core. The two intermediate layers and the outer layer are also in the form of approximate cylinders. The content of the core region, intermediate layers and the outer layer of the thread may be as described for the particles shown inFIGS. 4A, 4B and 4C . Threads according toFIG. 4D may be produced using the device shown inFIGS. 1 to 3B . It has been found that the formation of a threads can be promoted by dissolving or suspending a suitable material in a fluid medium in an appropriate concentration, this fluid medium being passed down one of the channels of the device. For example, threads have been found to be promoted if at least one of the fluid mediums being passed down the channels contains a polymeric material in an amount of 60% or more by weight. For example, threads have been found to be promoted if at least one of the fluid mediums being passed down the channels contains a non-polymeric material in an amount of 50% or more by weight. - The present invention further provides a composition comprising a plurality of bodies of the first aspect and/or a plurality of bodies of the second aspect. The plurality of bodies may contain a collection of bodies all according to the first aspect or the second aspect, but nevertheless having differing characteristics, for example being of different diameters and/or having different compositions.
- The present invention further provides a plurality of bodies obtainable by a method according to the fourth aspect and/or a method according to the fifth aspect. The plurality of bodies may contain a collection of bodies all obtainable by a method according to the fourth aspect and/or a method according to the fifth aspect, but nevertheless having differing characteristics, for example being of different diameters and/or having different compositions.
- The present invention will now be described in the following non-limiting Examples.
- The following Examples illustrate a process of producing layered bodies according to the present invention.
- The four-needle electrohydrodynamic device used in the Examples was as shown in
FIGS. 1 to 3B , and as described above. The dimensions of the needles was as shown inFIG. 2B , and the connectivity of each needle and channel as shown inFIGS. 1 and 2A . The flow rates of fluid mediums supplied to the channels were controlled by four high-precision programmable syringe pumps (available from Harvard PHD 4400, Apparatus, Edenbridge, UK), labelledSyringe FIG. 1 . - An electric field between the needles and a ring-shaped ground electrode (not shown in Figures, external and internal diameters of 20 and 15 mm, respectively) was controlled by a high-voltage generator (obtained from Glassman Europe Limited, Bramley, UK).
- The distance from the exit of the outer needle to the ground electrode (the working distance) was fixed at 12 mm in all the experiments. The flow of the liquids under the influence of the electric field was visualized using a video camera (LEICA S6D JVC-colour).
- Properties of the fluid mediums used in the Examples are given below in Table 1.
-
TABLE 1 Surface Electrical Density Viscosity tension conductivity Fluid Medium kgm−3 mPa s mNm−1 Sm−1 Perfluorohexane 1710 1.1 12 <1 × 10−11 Ethanol containing 805 1.8 23 9 × 10−5 18 wt % of PMSQ - The perfluorohexane represents an example of a second fluid medium as described herein. The ethanol containing 18 wt % of PMSQ represents an example of a first fluid medium as described herein.
- For the measurement of density, viscosity, surface tension and electrical conductivity, ethanol was used as the calibrating medium in the relevant measurement equipment used. The density of each fluid medium was measured using a standard 25 ml density bottle. The surface tension values of each fluid medium were measured using a Kruss Tensiometer. Viscosity values were determined using a U-tube viscometer and a VISCOEASY rotational viscometer. Electrical conductivity values were estimated using a HI-8733 conductivity probe.
- In this example, the
syringe 1 of the device was loaded with the compound PFH (perfluorohexane), obtained from F2 Chemicals Ltd. This was supplied to channel W at a rate of 300 μl per minute. -
Syringe 2 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ), obtained from Wacker Chemie AG, GmbH. This was supplied to channel X at a rate of 600 μl per minute. -
Syringe 3 was loaded with PFH. This was supplied to channel Y at a rate of 300 μl per minute. -
Syringe 4 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ). This was supplied to channel Z at a rate of 600 μl per minute. - The voltage applied to the needles was 20 kV.
- A jet was found to form, which broke up to form droplets or capsules, i.e. an embodiment of the layered bodies of the invention. It is considered that the cross section of the capsules may be represented schematically by
FIG. 4C . A collection of the capsules is shown inFIG. 5 . Scanning electron microscopy (SEM, JEOL JSM-6301F field emission scanning electron microscope) was used to obtain this image and study the size of the as-formed products. 200 microspheres were analyzed from the SEM images to calculate the mean diameter of the capsules, this mean being the number mean. The mean diameter of the capsules was found to be 510 nm. The maximum diameter of the capsules was found to be 1350 nm. The minimum diameter of the capsules was found to be 35 nm. - In this example, the
syringe 1 of the device was loaded with the compound PFH (perfluorohexane), obtained from F2 Chemicals Ltd. This was supplied to channel W at a rate of 300 μl per minute. -
Syringe 2 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ), obtained from Wacker Chemie AG, GmbH. This was supplied to channel X at a rate of 300 μl per minute. -
Syringe 3 was loaded with PFH. This was supplied to channel Y at a rate of 300 μl per minute. -
Syringe 4 was loaded with ethanol containing 18 wt % of the polymer polymethylsilsesquioxane (PMSQ). This was supplied to channel Z at a rate of 300 μl per minute. - The voltage applied to the needles was 20 kV.
- A jet was found to form, which broke up to form droplets or capsules, i.e. an embodiment of the layered bodies according to the invention. It is considered that the cross section of the capsules may be represented schematically by
FIG. 4C . A collection of the capsules is shown inFIG. 6 . Scanning electron microscopy (SEM, JEOL JSM-6301F field emission scanning electron microscope) was used to obtain this image and study the size of the as-formed products. 200 microspheres were analyzed from the SEM images to calculate the mean diameter of the capsules, this mean being the number mean. The mean diameter of the capsules was found to be 590 nm. The maximum diameter of the capsules was found to be 1062 nm. The maximum diameter of the capsules was found to be 233 nm.
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/833,436 US10780059B2 (en) | 2011-02-08 | 2017-12-06 | Process for producing layered bodies |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1102148.2A GB201102148D0 (en) | 2011-02-08 | 2011-02-08 | Layered bodies, compositions containing them and processes for producing them |
GB1102148.2 | 2011-02-08 | ||
PCT/GB2012/050276 WO2012107760A2 (en) | 2011-02-08 | 2012-02-08 | Layered bodies, compositions containing them and processes for producing them |
US201313984345A | 2013-10-14 | 2013-10-14 | |
US15/833,436 US10780059B2 (en) | 2011-02-08 | 2017-12-06 | Process for producing layered bodies |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/984,345 Division US20140050782A1 (en) | 2011-02-08 | 2012-02-08 | Layered Bodies, Compositions Containing Them and Processes for Producing Them |
PCT/GB2012/050276 Division WO2012107760A2 (en) | 2011-02-08 | 2012-02-08 | Layered bodies, compositions containing them and processes for producing them |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180104192A1 true US20180104192A1 (en) | 2018-04-19 |
US10780059B2 US10780059B2 (en) | 2020-09-22 |
Family
ID=43836373
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/984,345 Abandoned US20140050782A1 (en) | 2011-02-08 | 2012-02-08 | Layered Bodies, Compositions Containing Them and Processes for Producing Them |
US15/833,436 Active US10780059B2 (en) | 2011-02-08 | 2017-12-06 | Process for producing layered bodies |
US15/833,452 Active US10828263B2 (en) | 2011-02-08 | 2017-12-06 | Layered bodies and compositions containing them |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/984,345 Abandoned US20140050782A1 (en) | 2011-02-08 | 2012-02-08 | Layered Bodies, Compositions Containing Them and Processes for Producing Them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/833,452 Active US10828263B2 (en) | 2011-02-08 | 2017-12-06 | Layered bodies and compositions containing them |
Country Status (5)
Country | Link |
---|---|
US (3) | US20140050782A1 (en) |
EP (1) | EP2673079B1 (en) |
ES (1) | ES2784144T3 (en) |
GB (1) | GB201102148D0 (en) |
WO (1) | WO2012107760A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10836089B2 (en) * | 2014-02-20 | 2020-11-17 | Guill Tool & Engineering Co., Inc. | Multicomponent approach to standard and microlayer coextrusion |
US11771881B2 (en) | 2019-08-29 | 2023-10-03 | Toyota Motor Engineering & Manufacturing North America, Inc. | Needle adapter and device for soft material extrusion of core-shell structures |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3429827A (en) * | 1962-11-23 | 1969-02-25 | Moore Business Forms Inc | Method of encapsulation |
US6193951B1 (en) * | 1997-04-30 | 2001-02-27 | Point Biomedical Corporation | Microparticles useful as ultrasonic contrast agents |
US20040161498A1 (en) * | 2001-01-31 | 2004-08-19 | Kraft Foods Holdings, Inc. | Production of capsules and particles for improvement of food products |
US20050123614A1 (en) * | 2003-12-04 | 2005-06-09 | Kyekyoon Kim | Microparticles |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9003821D0 (en) * | 1990-02-20 | 1990-04-18 | Danbiosyst Uk | Diagnostic aid |
CA2070779A1 (en) * | 1990-10-09 | 1992-04-10 | Iver E. Anderson | Environmentally stable reactive alloy powders and method of making same |
US20040052984A1 (en) * | 1997-05-13 | 2004-03-18 | Toth Richard E. | Apparatus and method of treating fine powders |
US7101575B2 (en) * | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
US6063365A (en) | 1998-09-10 | 2000-05-16 | International Flavors & Fragrances Inc. | Application of film forming technology to fragrance control release systems; and resultant fragrance control release systems |
KR100902625B1 (en) | 2000-08-15 | 2009-06-15 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | Microparticles |
US6589562B1 (en) | 2000-10-25 | 2003-07-08 | Salvona L.L.C. | Multicomponent biodegradable bioadhesive controlled release system for oral care products |
US6767637B2 (en) * | 2000-12-13 | 2004-07-27 | Purdue Research Foundation | Microencapsulation using ultrasonic atomizers |
US6491902B2 (en) | 2001-01-29 | 2002-12-10 | Salvona Llc | Controlled delivery system for hair care products |
ES2180405B1 (en) | 2001-01-31 | 2004-01-16 | Univ Sevilla | DEVICE AND PROCEDURE FOR PRODUCING MULTICOMPONENT COMPOSITE LIQUID JEANS AND MULTICOMPONENT AND / OR MULTI-PAPER MICRO AND NANOMETRIC SIZE CAPSULES. |
US6805904B2 (en) | 2002-02-20 | 2004-10-19 | International Business Machines Corporation | Process of forming a multilayer nanoparticle-containing thin film self-assembly |
US6825161B2 (en) | 2002-04-26 | 2004-11-30 | Salvona Llc | Multi component controlled delivery system for soap bars |
US7544770B2 (en) | 2003-08-29 | 2009-06-09 | Louisiana Tech Foundation, Inc. | Multilayer films, coatings, and microcapsules comprising polypeptides |
US20050163714A1 (en) | 2003-10-02 | 2005-07-28 | Sukhishvili Svetlana A. | Capsules of multilayered neutral polymer films associated by hydrogen bonding |
US7744644B2 (en) | 2004-03-19 | 2010-06-29 | Boston Scientific Scimed, Inc. | Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release |
US7736582B2 (en) * | 2004-06-10 | 2010-06-15 | Allomet Corporation | Method for consolidating tough coated hard powders |
DE102004034355B4 (en) * | 2004-07-13 | 2007-03-22 | Fachhochschule Jena | Capsule for releasing active substances located in it at defined locations in a body |
US20060099247A1 (en) * | 2004-11-10 | 2006-05-11 | Byrd-Walsh, Llc. | Liquid, gas and/or vapor phase delivery systems |
WO2007063615A1 (en) | 2005-11-30 | 2007-06-07 | Juridical Foundation Osaka Industrial Promotion Organization | Catalyst encapsulated in hollow porous capsule and process for producing the same |
US20080187487A1 (en) * | 2006-05-03 | 2008-08-07 | Gustavo Larsen | Methods for producing multilayered particles, fibers and sprays and methods for administering the same |
DE102006028915A1 (en) | 2006-06-23 | 2007-12-27 | Robert Bosch Gmbh | Preparing porous silicon hollow body, used in producing dosage unit to treat e.g. pain, comprises passivating and masking the surface of silicon body, anisotropic etching, porosifying the canal of silicon and electro polishing |
EP2068844A4 (en) * | 2006-09-04 | 2013-01-23 | Panacea Biotec Ltd | Programmable buoyant delivery technology |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
GB0706175D0 (en) | 2007-03-29 | 2007-05-09 | Ucl Business Plc | System and method for microbubble production |
US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
-
2011
- 2011-02-08 GB GBGB1102148.2A patent/GB201102148D0/en not_active Ceased
-
2012
- 2012-02-08 ES ES12708151T patent/ES2784144T3/en active Active
- 2012-02-08 EP EP12708151.1A patent/EP2673079B1/en active Active
- 2012-02-08 WO PCT/GB2012/050276 patent/WO2012107760A2/en active Application Filing
- 2012-02-08 US US13/984,345 patent/US20140050782A1/en not_active Abandoned
-
2017
- 2017-12-06 US US15/833,436 patent/US10780059B2/en active Active
- 2017-12-06 US US15/833,452 patent/US10828263B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3429827A (en) * | 1962-11-23 | 1969-02-25 | Moore Business Forms Inc | Method of encapsulation |
US6193951B1 (en) * | 1997-04-30 | 2001-02-27 | Point Biomedical Corporation | Microparticles useful as ultrasonic contrast agents |
US20040161498A1 (en) * | 2001-01-31 | 2004-08-19 | Kraft Foods Holdings, Inc. | Production of capsules and particles for improvement of food products |
US20050123614A1 (en) * | 2003-12-04 | 2005-06-09 | Kyekyoon Kim | Microparticles |
US20080181964A1 (en) * | 2003-12-04 | 2008-07-31 | Kyekyoon Kim | Microparticles |
Non-Patent Citations (1)
Title |
---|
Chang et al. Stimulus-responsive liquids for encapsulation storage and controlled release of drugs from nano-shell capsules. J. R. Soc. Interface (2011) 8, 451–456. (Year: 2011) * |
Also Published As
Publication number | Publication date |
---|---|
EP2673079B1 (en) | 2020-01-08 |
ES2784144T3 (en) | 2020-09-22 |
WO2012107760A2 (en) | 2012-08-16 |
US20180092860A1 (en) | 2018-04-05 |
EP2673079A2 (en) | 2013-12-18 |
US10828263B2 (en) | 2020-11-10 |
WO2012107760A3 (en) | 2013-01-03 |
US10780059B2 (en) | 2020-09-22 |
GB201102148D0 (en) | 2011-03-23 |
US20140050782A1 (en) | 2014-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11007297B2 (en) | Process for making aligned or twisted electrospun fibers | |
Key et al. | Soft discoidal polymeric nanoconstructs resist macrophage uptake and enhance vascular targeting in tumors | |
US20150359886A1 (en) | System and methods for nanostructure protected delivery of treatment agent and selective release thereof | |
Pisani et al. | Polymeric nano/microcapsules of liquid perfluorocarbons for ultrasonic imaging: physical characterization | |
Shinde et al. | Nanoparticles: Advances in drug delivery systems | |
CN104321051B (en) | Non-woven membrane as drug delivery system | |
US20140147510A1 (en) | Multiphasic polymeric particles capable of shape-shifting via environmental stimulation | |
US10828263B2 (en) | Layered bodies and compositions containing them | |
KR101493444B1 (en) | Polycaprolactone nano-fibers comprising physiological active substance and manufacturing method thereof | |
Kapahi et al. | Implication of nanofibers in oral drug delivery | |
Ali et al. | Electrohydrodynamic atomisation driven design and engineering of opportunistic particulate systems for applications in drug delivery, therapeutics and pharmaceutics | |
Vlachou et al. | Electrospinning and drug delivery | |
Rai et al. | Concepts on smart nano-based drug delivery system | |
Feng et al. | Vitamin E TPGS-emulsified poly (lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment | |
JP7422793B2 (en) | emulsion containing particles | |
Zare et al. | Current progress of electrospun nanocarriers for drug delivery applications | |
do Nascimento Soares et al. | Electrospun progesterone‐loaded cellulose acetate nanofibers and their drug sustained‐release profiles | |
Xiang et al. | Electrospinning using a Teflon-coated spinneret | |
Chang et al. | A novel process for drug encapsulation using a liquid to vapour phase change material | |
TWI483747B (en) | Drug carrier and preparation method thereof | |
Purohit et al. | An overview of the recent developments and patents in the field of pharmaceutical nanotechnology | |
US20210300810A1 (en) | Porous Glass Microspheres, Composite Materials and Methods of Using Same | |
Baptista et al. | Nanofibers and nanoparticles in biomedical applications | |
EP3374076A1 (en) | Microbubbles and their generation | |
US20230270681A1 (en) | Drug delivery agents for prevention or treatment of pulmonary disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UCL BUSINESS PLC, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EDIRISINGHE, MOHAN;CHANG, MING WEI;STRIDE, ELEANOR;SIGNING DATES FROM 20130910 TO 20130918;REEL/FRAME:044318/0116 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
AS | Assignment |
Owner name: UCL BUSINESS LTD, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:UCL BUSINESS PLC;REEL/FRAME:053328/0130 Effective date: 20190828 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |